

2010 update of the ASAS/EULAR recommendations for spondylitis

Annals of the Rheumatic Diseases

70, 896-904

DOI: [10.1136/ard.2011.151027](https://doi.org/10.1136/ard.2011.151027)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Current therapeutics for spondyloarthritis. Expert Opinion on Pharmacotherapy, 2011, 12, 2469-2477.	0.9	7
3	Neck Pain from a Rheumatologic Perspective. Physical Medicine and Rehabilitation Clinics of North America, 2011, 22, 485-502.	0.7	2
4	Celecoxib. Drugs, 2011, 71, 2457-2489.	4.9	185
5	2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Annals of the Rheumatic Diseases, 2011, 70, 905-908.	0.5	365
7	Antiinflamatorios no esteroideos: farmacodinámica, reacciones adversas e indicaciones en reumatología. Medicine, 2011, 10, 6255-6261.	0.0	0
8	Turkish League Against Rheumatism National Recommendations for the Management of Ankylosing Spondylitis. Turkish Journal of Rheumatology, 2011, 26, 173-186.	0.2	8
9	Seronegative Spondyloarthropathies: Evolving Concepts Regarding Diagnosis and Treatment. Journal of Spine, 2011, 01, .	0.2	2
10	Improving diagnosis of ankylosing spondylitis and spondyloarthritis in general. International Journal of Clinical Rheumatology, 2011, 6, 655-667.	0.3	0
11	Glucocorticoids. Best Practice and Research in Clinical Rheumatology, 2011, 25, 891-900.	1.4	65
12	Spondyloarthritides. Best Practice and Research in Clinical Rheumatology, 2011, 25, 825-842.	1.4	35
14	NSAIDs for RA, osteoarthritis and ankylosing spondylitis. The Prescriber, 2011, 22, 26-29.	0.1	3
15	Significance of sacroiliac joint aereocele in diagnosis of ankylosing spondylitis. Journal of Shanghai Jiaotong University (Science), 2011, 16, 636-640.	0.5	1
16	Rehabilitation for Ankylosing Spondylitis in the Era of Biologics: Any Room Left for This Treatment?. Journal of Rheumatology, 2011, 38, 1228-1230.	1.0	13
17	Integrative Structural Biomechanical Concepts of Ankylosing Spondylitis. Arthritis, 2011, 2011, 1-10.	2.0	14
18	A discrete event modelling framework for simulation of long-term outcomes of sequential treatment strategies for ankylosing spondylitis. Annals of the Rheumatic Diseases, 2011, 70, 2111-2118.	0.5	11
19	Management of ASAS new guidelines in the spotlight. Nature Reviews Rheumatology, 2011, 7, 504-505.	3.5	0
20	Methotrexate in peripheral spondyloarthritis including psoriatic arthritis: a need for further evaluation. Rheumatology, 2012, 51, 1343-1344.	0.9	17
21	First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Rheumatology, 2012, 51, 1388-1396.	0.9	112

#	ARTICLE	IF	CITATIONS
22	Sacroiliac Joint Injections in Patients with Sacroiliitis: Which is the Right Way?. Turkish Journal of Rheumatology, 2012, 27, 149-151.	0.2	0
23	Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2012, 71, 700-706.	0.5	80
24	Referral strategies for early diagnosis of axial spondyloarthritis. Nature Reviews Rheumatology, 2012, 8, 262-268.	3.5	111
25	Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition. Current Opinion in Rheumatology, 2012, 24, 252-260.	2.0	30
26	Baseline predictors of response to TNF- β blocking therapy in ankylosing spondylitis. Current Opinion in Rheumatology, 2012, 24, 290-298.	2.0	33
27	Management and evaluation of extra-articular manifestations in spondyloarthritis. Therapeutic Advances in Musculoskeletal Disease, 2012, 4, 413-422.	1.2	49
28	Drug therapy of inflammatory arthritis. Clinical Medicine, 2012, 12, 357-363.	0.8	9
29	Late-Onset Spondyloarthritis: Subset That Should Not Be Forgotten. Journal of Rheumatology, 2012, 39, 1110-1112.	1.0	14
33	Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents. Journal of Medical Economics, 2012, 15, 1054-1063.	1.0	44
34	Terapia mĂ©dica actual en reumatologĂ­a. Revista MĂ©dica ClĂ­nica Las Condes, 2012, 23, 413-422.	0.2	0
35	Prevalence and Risk Factors of Anterior Atlantoaxial Subluxation in Ankylosing Spondylitis. Journal of Rheumatology, 2012, 39, 2321-2326.	1.0	23
36	Emerging concepts in ankylosing spondylitis. International Journal of Clinical Rheumatology, 2012, 7, 515-526.	0.3	0
37	Efficacy of Incentive Spirometer Exercise on Pulmonary Functions of Patients with Ankylosing Spondylitis Stabilized by Tumor Necrosis Factor Inhibitor Therapy. Journal of Rheumatology, 2012, 39, 1854-1858.	1.0	30
38	Genetic polymorphisms inside and outside the MHC improve prediction of AS radiographic severity in addition to clinical variables. Rheumatology, 2012, 51, 1471-1478.	0.9	18
39	Can Imaging Be Used for Inflammatory Arthritis Screening?. Seminars in Musculoskeletal Radiology, 2012, 16, 401-409.	0.4	13
40	Physical Fitness in Patients With Ankylosing Spondylitis: Comparison With Population Controls. Physical Therapy, 2012, 92, 298-309.	1.1	43
41	Management of Ankylosing Spondylitis: What Is Known; What Is Not Known?. American Journal of the Medical Sciences, 2012, 343, 343-344.	0.4	0
42	Imaging and Clinical Measurements. American Journal of the Medical Sciences, 2012, 343, 345-349.	0.4	0

#	ARTICLE	IF	CITATIONS
43	Juvenile Spondyloarthritis Treatment Recommendations. American Journal of the Medical Sciences, 2012, 343, 367-370.	0.4	16
44	Critical Appraisal of the Guidelines for the Management of Ankylosing Spondylitis: Disease-Modifying Antirheumatic Drugs. American Journal of the Medical Sciences, 2012, 343, 357-359.	0.4	5
45	The "Knowns" and "Unknowns" of Biologic Therapy in Ankylosing Spondylitis. American Journal of the Medical Sciences, 2012, 343, 360-363.	0.4	4
46	Conventional <sc>DMARD</sc> therapy (methotrexate+sulphasalazine) may decrease the requirement of biologics in routine practice of ankylosing spondylitis patients: A real-life experience. International Journal of Rheumatic Diseases, 2012, 15, 526-530.	0.9	12
47	Early diagnosis and treatment of ankylosing spondylitis in Africa and the Middle East. Clinical Rheumatology, 2012, 31, 1633-1639.	1.0	20
48	Should We Consider Tumor Necrosis Factor as the Only Target in Spondyloarthritis?. Journal of rheumatology Supplement, The, 2012, 89, 94-96.	2.2	2
49	Rituximab in a patient with ankylosing spondylitis with demyelinating disease: a case report and review of the literature. Clinical Rheumatology, 2012, 31, 1259-1261.	1.0	11
50	Early Spondyloarthritis. Rheumatic Disease Clinics of North America, 2012, 38, 387-403.	0.8	46
51	Therapy for Spondyloarthritis. Rheumatic Disease Clinics of North America, 2012, 38, 583-600.	0.8	8
52	Preface. Rheumatic Disease Clinics of North America, 2012, 38, xvii-xxi.	0.8	0
53	How Important is Early Therapy in Axial Spondyloarthritis?. Rheumatic Disease Clinics of North America, 2012, 38, 635-642.	0.8	17
54	Therapeutic Controversies in Spondyloarthritis. Rheumatic Disease Clinics of North America, 2012, 38, 601-611.	0.8	21
55	A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis. Modern Rheumatology, 2012, 22, 589-597.	0.9	16
57	NSAIDs and radiographic progression in ankylosing spondylitis Bagging big game with small arms?. Annals of the Rheumatic Diseases, 2012, 71, 1593-1595.	0.5	40
58	Biologic Therapies for Spondyloarthritis: What Is New?. Current Rheumatology Reports, 2012, 14, 422-427.	2.1	35
59	Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2012, 71, 1623-1629.	0.5	223
60	Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Annals of the Rheumatic Diseases, 2012, 71, 1616-1622.	0.5	286
61	Developments in therapies for spondyloarthritis. Nature Reviews Rheumatology, 2012, 8, 280-287.	3.5	47

#	ARTICLE	IF	CITATIONS
62	Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?. <i>Arthritis Research and Therapy</i> , 2012, 14, R216.	1.6	58
64	Comorbidities in Patients with Spondyloarthritis. <i>Rheumatic Disease Clinics of North America</i> , 2012, 38, 523-538.	0.8	33
65	Pathophysiology and Role of the Gastrointestinal System in Spondyloarthritis. <i>Rheumatic Disease Clinics of North America</i> , 2012, 38, 569-582.	0.8	30
66	New advances in juvenile spondyloarthritis. <i>Nature Reviews Rheumatology</i> , 2012, 8, 269-279.	3.5	74
67	Regression of syndesmophyte after bone marrow transplantation for acute myeloid leukemia in a patient with ankylosing spondylitis: a case report. <i>Journal of Medical Case Reports</i> , 2012, 6, 250.	0.4	8
68	Update on the Management of Spondyloarthritis in Asian Countries. <i>Current Rheumatology Reviews</i> , 2012, 8, 39-44.	0.4	3
69	Agreement of Turkish Physiatrists with the Assessment in Spondyloarthritis International Society and the European League Against Rheumatism Recommendations for the Management of Ankylosing Spondylitis and Rheumatoid Arthritis. <i>Open Rheumatology Journal</i> , 2012, 6, 1-5.	0.1	1
70	Tailored Treatment of Ankylosing Spondylitis. <i>Hanyang Medical Reviews</i> , 2012, 32, 77.	0.4	0
71	Adaptao cultural cruzada e validao da verso do ndice Funcional de Espondilite Anquilosante de Bath (BASFI) para o portugus do Brasil. <i>Revista Brasileira De Reumatologia</i> , 2012, 52, 737-741.	0.8	5
74	Expert opinion and key recommendations for the physical therapy and rehabilitation of patients with ankylosing spondylitis. <i>International Journal of Rheumatic Diseases</i> , 2012, 15, 229-238.	0.9	55
75	Predictors of Chikungunya rheumatism: a prognostic survey ancillary to the TELECHIK cohort study. <i>Arthritis Research and Therapy</i> , 2013, 15, R9.	1.6	97
76	Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)?. <i>Arthritis Research and Therapy</i> , 2013, 15, R14.	1.6	48
77	Short term in-patient rehabilitation in axial spondyloarthritis - the results of a 2-week program performed in daily clinical practice. <i>BMC Research Notes</i> , 2013, 6, 185.	0.6	15
78	Opinion: Perspectives on imaging in axial spondyloarthritis. <i>Nature Reviews Rheumatology</i> , 2013, 9, 498-502.	3.5	17
80	Phosphodiesterase 4-targeted treatments for autoimmune diseases. <i>BMC Medicine</i> , 2013, 11, 96.	2.3	96
81	Treatment Challenges in Axial Spondylarthritis and Future Directions. <i>Current Rheumatology Reports</i> , 2013, 15, 356.	2.1	5
82	High disease activity is related to low levels of physical activity in patients with ankylosing spondylitis. <i>Clinical Rheumatology</i> , 2013, 32, 1719-1725.	1.0	34
83	Core set of recommendations for patients with ankylosing spondylitis concerning behaviour and environmental adaptations. <i>Rheumatology International</i> , 2013, 33, 2343-2349.	1.5	23

#	ARTICLE	IF	CITATIONS
84	Home-based exercise therapy in ankylosing spondylitis: short-term prospective study in patients receiving tumor necrosis factor alpha inhibitors. <i>Rheumatology International</i> , 2013, 33, 71-77.	1.5	36
85	Spondyloarthritis and inflammatory bowel disease. <i>Zeitschrift Fur Rheumatologie</i> , 2013, 72, 524-529.	0.5	11
86	Frequency of fragmented QRS in ankylosing spondylitis. <i>Zeitschrift Fur Rheumatologie</i> , 2013, 72, 468-473.	0.5	8
89	Coexistence of Multiple Sclerosis and Ankylosing Spondylitis: Report of Two Cases. <i>European Neurology</i> , 2013, 70, 149-154.	0.6	8
90	Do non-steroidal anti-inflammatory drugs have disease-modifying effects in spondyloarthritis?. <i>Joint Bone Spine</i> , 2013, 80, 563-564.	0.8	11
92	Lower Extremity Arthroplasty in Patients With Inflammatory Arthritis: Preoperative and Perioperative Management. <i>Journal of the American Academy of Orthopaedic Surgeons, The</i> , 2013, 21, 355-363.	1.1	18
93	Remission in ankylosing spondylitis treated with anti-TNF- α drugs: a national multicentre study. <i>Rheumatology</i> , 2013, 52, 1914-1919.	0.9	60
94	Update on Juvenile Spondyloarthritis. <i>Rheumatic Disease Clinics of North America</i> , 2013, 39, 767-788.	0.8	40
95	Early diagnosis and management are crucial in spondyloarthritis. <i>Joint Bone Spine</i> , 2013, 80, 582-585.	0.8	46
96	Outcome assessment in axial spondyloarthritis-imaging techniques, their relation to outcomes and their use in clinical trials. <i>Indian Journal of Rheumatology</i> , 2013, 8, S38-S43.	0.2	1
97	Daily physical activity in ankylosing spondylitis: validity and reliability of the IPAQ and SQUASH and the relation with clinical assessments. <i>Arthritis Research and Therapy</i> , 2013, 15, R99.	1.6	49
98	Golimumab: A Novel Anti-Tumor Necrosis Factor. <i>Biologics in Therapy</i> , 2013, 3, 83-107.	1.8	6
100	Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis â€” a five-year update. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1599-1611.	1.4	9
101	Disease-modifying anti-rheumatic drugs for refractory severe knee synovitis in patients with peripheral spondyloarthritis: efficacy and predictors of response. <i>Scandinavian Journal of Rheumatology</i> , 2013, 42, 369-372.	0.6	1
102	EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1125-1135.	0.5	1,033
103	MR-defined fat infiltration of the lumbar paravertebral muscles differs between non-radiographic axial spondyloarthritis and established ankylosing spondylitis. <i>Modern Rheumatology</i> , 2013, 23, 811-816.	0.9	21
104	Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1475-1480.	0.5	107
105	Female patients with ankylosing spondylitis: analysis of the impact of gender across treatment studies. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1221-1224.	0.5	113

#	ARTICLE	IF	CITATIONS
106	Elevated serum levels of high mobility group box protein 1 (HMGB1) in patients with ankylosing spondylitis and its association with disease activity and quality of life. <i>Rheumatology International</i> , 2013, 33, 1327-1331.	1.5	34
109	Pourquoi un diagnostic et une prise en charge précoces des spondyloarthrites?. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2013, 80, 435-438.	0.0	3
110	Efficacité de l'éducation thérapeutique du patient dans les rhumatismes inflammatoires: quelles preuves?. <i>Revue Du Rhumatisme Monographies</i> , 2013, 80, 170-173.	0.0	2
112	Évaluation de l'activité de la spondylarthrite par les patients et les médecins: ASDAS, BASDAI, PASS et poussées. À propos de 200 cas. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2013, 80, 244-249.	0.0	0
113	Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. <i>Rheumatology International</i> , 2013, 33, 2199-2213.	1.5	78
114	Etanercept for the treatment of axial spondyloarthritis. <i>Clinical Investigation</i> , 2013, 3, 343-357.	0.0	0
115	Evaluation of spondylarthritis activity by patients and physicians: ASDAS, BASDAI, PASS, and flares in 200 patients. <i>Joint Bone Spine</i> , 2013, 80, 393-398.	0.8	47
116	A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1605-1612.	0.5	531
117	Safety of tumor necrosis factor inhibitors use for rheumatoid arthritis and ankylosing spondylitis in Africa, the Middle East, and Asia: focus on severe infections and tuberculosis. <i>Clinical Rheumatology</i> , 2013, 32, 293-300.	1.0	10
119	Recent updates on the recommendations for the management of ankylosing spondylitis: what and why?. <i>International Journal of Clinical Rheumatology</i> , 2013, 8, 361-371.	0.3	1
120	Rehabilitation and surgical management of ankylosing spondylitis. <i>Musculoskeletal Surgery</i> , 2013, 97, 191-195.	0.7	13
121	OP0080...Aerobic training in patients with ankylosing spondylitis: A randomized controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 80.2-80.	0.5	0
122	A three-week multidisciplinary in-patient rehabilitation programme had positive long-term effects in patients with ankylosing spondylitis: Randomized controlled trial. <i>Journal of Rehabilitation Medicine</i> , 2013, 45, 260-267.	0.8	75
123	Invited Commentary. <i>Radiographics</i> , 2013, 33, 956-961.	1.4	0
124	Therapeutics for the treatment of spondyloarthritis: what, when and whom. <i>International Journal of Clinical Rheumatology</i> , 2013, 8, 73-88.	0.3	0
128	Conflicts of interest in biomedical publications: considerations for authors, peer reviewers, and editors. <i>Croatian Medical Journal</i> , 2013, 54, 600-608.	0.2	39
129	Axial spondyloarthritis: is there a treatment of choice?. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2013, 5, 45-54.	1.2	36
130	Hip disease in ankylosing spondylitis. <i>Current Opinion in Rheumatology</i> , 2013, 25, 448-454.	2.0	69

#	ARTICLE	IF	CITATIONS
131	Psoriatic arthritis and spondyloarthritis assessment and management update. Current Opinion in Rheumatology, 2013, 25, 287-296.	2.0	51
133	Patients'™ needs and expectations with regard to rheumatology nursing care: results of multicentre focus group interviews. Annals of the Rheumatic Diseases, 2013, 72, 831-835.	0.5	36
134	Associations between inflammation, nocturnal back pain and fatigue in ankylosing spondylitis and improvements with etanercept therapy. Journal of International Medical Research, 2013, 41, 1150-1159.	0.4	18
135	Defects in Tendon, Ligament, and Enthesis in Response to Genetic Alterations in Key Proteoglycans and Glycoproteins: A Review. Arthritis, 2013, 2013, 1-30.	2.0	54
136	Effect of Cardiovascular Training on Fitness and Perceived Disease Activity in People With Ankylosing Spondylitis. Arthritis Care and Research, 2013, 65, 1844-1852.	1.5	61
137	Patient satisfaction with nursing consultations in a rheumatology outpatient clinic: a 21-month randomised controlled trial in patients with inflammatory arthritides. Annals of the Rheumatic Diseases, 2013, 72, 836-843.	0.5	59
138	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012: Table A1. Annals of the Rheumatic Diseases, 2013, 72, ii2-ii34.	0.5	114
139	Consensus of Chinese Orthopaedic Experts on Diagnosis and Treatment of Ankylosing Spondylitis. Orthopaedic Surgery, 2013, 5, 1-5.	0.7	4
141	Development, Sensibility, and Reliability of the Toronto Axial Spondyloarthritis Questionnaire in Inflammatory Bowel Disease. Journal of Rheumatology, 2013, 40, 1726-1735.	1.0	20
142	Certolizumab pegol in axial spondyloarthritis. Expert Review of Clinical Immunology, 2013, 9, 1161-1172.	1.3	5
143	Advances in the Management of Ankylosing Spondylitis. , 2013, , .		0
144	The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. Rheumatology, 2013, 52, 1754-1757.	0.9	79
145	Treatment Recommendations for the Management of Axial Spondyloarthritis. American Journal of the Medical Sciences, 2013, 345, 426-430.	0.4	2
146	New developments in the diagnosis and treatment of axial spondyloarthritis. Clinical Investigation, 2013, 3, 153-171.	0.0	0
147	OP0078-HPR. A three week rehabilitation program had positive long term effects in patients with ankylosing spondylitis: Results from a randomised controlled trial. Annals of the Rheumatic Diseases, 2013, 71, 79.3-80.	0.5	0
149	Physiotherapy and rehabilitation in ankylosing spondylitis: is it still the mainstay of management in the era of biologics?. International Journal of Clinical Rheumatology, 2013, 8, 579-584.	0.3	1
151	South African guideline for the use of chronic opioid therapy for chronic non-cancer pain. South African Medical Journal, 2013, 104, 78.	0.2	6
152	Anti-TNF agents for the treatment of active non-radiographic axial spondyloarthritis. Reumatismo, 2013, 65, 1-3.	0.4	0

#	ARTICLE	IF	CITATIONS
153	A Case of Etanercept Treatment in a Patient with Ankylosing Spondylitis on Peritoneal Dialysis. <i>Journal of Rheumatic Diseases</i> , 2013, 20, 361.	0.4	0
154	How to Translate Basic Knowledge into Clinical Application of Biologic Therapy in Spondyloarthritis. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-6.	3.3	11
155	Prevalence of Self-Reported Spondyloarthritis Features in a Cohort of Patients with Inflammatory Bowel Disease. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2013, 27, 199-205.	1.8	53
156	Spondyloarthritides. , 2013, , 137-187.		0
157	Eye Infection Complications in Rheumatic Diseases. , 2013, , .		3
158	Increased Risk of Ischemic Stroke in Young Patients with Ankylosing Spondylitis: A Population-Based Longitudinal Follow-Up Study. <i>PLoS ONE</i> , 2014, 9, e94027.	1.1	28
159	Medical Treatment of Ankylosing Spondylitis. <i>Hip and Pelvis</i> , 2014, 26, 129-135.	0.6	20
160	Efficacy and safety of adalimumab in ankylosing spondylitis. <i>Open Access Rheumatology: Research and Reviews</i> , 2014, 6, 83.	0.8	11
161	Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNF α drugs. <i>Reumatismo</i> , 2014, 66, 208-214.	0.4	11
162	Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?. <i>Reumatismo</i> , 2014, 66, 285-303.	0.4	5
163	Rheumatologic rehabilitation: towards recommendations. <i>Reumatismo</i> , 2014, 66, 197-207.	0.4	2
164	Active axial spondyloarthritis: potential role of certolizumab pegol. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 87.	0.9	0
165	Pulmonary Cryptococcosis in a Patient with Ankylosing Spondylitis treated with Etanercept. <i>Journal of Rheumatic Diseases</i> , 2014, 21, 214.	0.4	0
166	Orthotic Correction of Postural Unleveling in a Patient With Ankylosing Spondylitis. <i>Journal of Osteopathic Medicine</i> , 2014, 114, 125-128.	0.4	2
167	Use of Synthetic and Biological DMARDs in Treatment of Ankylosing Spondylitis at a University Hospital. <i>Internal Medicine: Open Access</i> , 2014, 04, .	0.0	0
168	Sulfasalazine for ankylosing spondylitis. <i>The Cochrane Library</i> , 2014, , CD004800.	1.5	55
169	Health-related quality of life in patients with ankylosing spondylitis: a comprehensive review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 857-872.	0.7	63
170	Whole body hyperthermia treatment increases interleukin 10 and toll-like receptor 4 expression in patients with ankylosing spondylitis: A pilot study. <i>International Journal of Hyperthermia</i> , 2014, 30, 393-401.	1.1	15

#	ARTICLE	IF	CITATIONS
171	Physical activity guidelines: is the message getting through to adults with rheumatic conditions?. <i>Rheumatology</i> , 2014, 53, 1812-1817.	0.9	28
173	Etanercept in the treatment of ankylosing spondylitis: A systematic review and meta-analysis. <i>Experimental and Therapeutic Medicine</i> , 2014, 8, 1585-1592.	0.8	10
174	Efficacy of Intensive Physiotherapy in Combination with Low-dose Etanercept in Active Spondyloarthritis: A Monocentric Pilot Study. <i>Journal of Rheumatology</i> , 2014, 41, 1897-1898.	1.0	18
175	Adipokines, Biomarkers of Endothelial Activation, and Metabolic Syndrome in Patients with Ankylosing Spondylitis. <i>BioMed Research International</i> , 2014, 2014, 1-11.	0.9	33
176	Axial spondyloarthritis: diagnosis and management. <i>The Prescriber</i> , 2014, 25, 32-36.	0.1	3
177	Validation of the educational needs assessment tool as a generic instrument for rheumatic diseases in seven European countries. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2122-2129.	0.5	37
178	Identifying Axial Spondyloarthritis in Dutch Primary Care Patients, Ages 20â€“45 Years, With Chronic Low Back Pain. <i>Arthritis Care and Research</i> , 2014, 66, 446-453.	1.5	80
179	Pharmacologic treatment of psoriatic arthritis and axial spondyloarthritis with traditional biologic and non-biologic DMARDs. <i>Best Practice and Research in Clinical Rheumatology</i> , 2014, 28, 793-806.	1.4	8
180	Adverse effects of TNF inhibitors in SpA: Are they different from RA?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2014, 28, 747-763.	1.4	20
181	Nonpharmacologic therapies in spondyloarthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2014, 28, 779-792.	1.4	16
182	Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2014, 28, 807-818.	1.4	22
183	Diffuse sclerosing osteomyelitis (DSO) of the mandible in SAPHO syndrome: A novel approach with anti-TNF therapy. Systematic review. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2014, 42, 1990-1996.	0.7	35
184	Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2014, 28, 711-728.	1.4	29
185	Clinical and economic impact of the use of etanercept 25 mg once weekly in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 145-150.	1.4	18
186	Consensus statement on the investigation and management of nonâ€“radiographic axial spondyloarthritis (nrâ€“ax<sc>S</sc>p<sc>A</sc>). <i>International Journal of Rheumatic Diseases</i> , 2014, 17, 548-556.	0.9	10
187	Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study. <i>Arthritis Research and Therapy</i> , 2014, 16, 481.	1.6	27
188	Similarities and differences between nonradiographic and radiographic axial spondyloarthritis. <i>Current Opinion in Rheumatology</i> , 2014, 26, 377-383.	2.0	58
189	Remission Thresholds in Spondyloarthritis: A Prospective Study in Current Practice. <i>Journal of Rheumatology</i> , 2014, 41, 617-618.	1.0	9

#	ARTICLE	IF	CITATIONS
190	Tumor necrosis factor-alpha inhibitor combined with methotrexate for ankylosing spondylitis: a systematic review and meta-analysis. <i>Rheumatology Reports</i> , 2014, 6, .	0.1	1
191	Supervised training and home-based rehabilitation in patients with stabilized ankylosing spondylitis on TNF inhibitor treatment: a controlled clinical trial with a 12-month follow-up. <i>Clinical Rehabilitation</i> , 2014, 28, 562-572.	1.0	34
192	Referral Patterns, Diagnosis, and Disease Management of Patients With Axial Spondyloarthritis. <i>Journal of Clinical Rheumatology</i> , 2014, 20, 411-417.	0.5	24
193	Randomized controlled trial of a nurse-led rheumatology clinic for monitoring biological therapy. <i>Journal of Advanced Nursing</i> , 2014, 70, 164-175.	1.5	40
194	Recommendations of the French Society for Rheumatology (SFR) on the everyday management of patients with spondyloarthritis. <i>Joint Bone Spine</i> , 2014, 81, 6-14.	0.8	85
195	Profile of the use of disease modifying drugs in the Brazilian Registry of Spondyloarthritis. <i>Revista Brasileira De Reumatologia</i> , 2014, 54, 33-37.	0.7	3
196	The use of anti-TNF therapy for ankylosing spondylitis in everyday rheumatology practice and the relationship to disease activity, work disability and diagnostic delay. <i>Irish Journal of Medical Science</i> , 2014, 183, 579-584.	0.8	8
197	Decreased plasma levels of soluble CD18 link leukocyte infiltration with disease activity in spondyloarthritis. <i>Arthritis Research and Therapy</i> , 2014, 16, R42.	1.6	22
198	Exercise therapy for spondyloarthritis: a systematic review. <i>Rheumatology International</i> , 2014, 34, 887-902.	1.5	87
199	Effects of Pilates, McKenzie and Heckscher training on disease activity, spinal motility and pulmonary function in patients with ankylosing spondylitis: a randomized controlled trial. <i>Rheumatology International</i> , 2014, 34, 367-372.	1.5	51
200	Is magnetotherapy applied to bilateral hips effective in Ankylosing spondylitis patients? A randomized, double-blind, controlled study. <i>Rheumatology International</i> , 2014, 34, 357-365.	1.5	10
201	Standards of care for patients with spondyloarthritis. <i>Rheumatology International</i> , 2014, 34, 165-170.	1.5	17
202	Safe Prescription Recommendations for Non Steroidal Anti-inflammatory Drugs: Consensus Document Elaborated by Nominated Experts of Three Scientific Associations (SER-SEC-AEG). <i>Reumatologia Clínica (English Edition)</i> , 2014, 10, 68-84.	0.2	9
203	Should non-steroidal anti-inflammatory drugs be used continuously in ankylosing spondylitis?. <i>Joint Bone Spine</i> , 2014, 81, 308-312.	0.8	9
204	Recommandations de la Société française de rhumatologie (SFR) pour la prise en charge en pratique courante des malades atteints de spondyloarthrite. <i>Revue Du Rhumatisme (Edition Française)</i> , 2014, 81, 6-15.	0.0	5
205	Clinician's Manual on Axial Spondyloarthritis. , 2014, , .		3
206	Therapeutic Options After Treatment Failure in Rheumatoid Arthritis or Spondyloarthritis. <i>Advances in Therapy</i> , 2014, 31, 780-802.	1.3	2
207	Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 238-242.	0.5	65

#	ARTICLE	IF	CITATIONS
208	Chronic inflammatory diseases: Do immunological patterns drive the choice of biotechnology drugs? A critical review. <i>Autoimmunity</i> , 2014, 47, 287-306.	1.2	16
210	Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 587-594.	0.5	80
211	Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 95-100.	0.5	181
212	Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 243-246.	0.5	83
213	ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2014, 10, 204-209.	0.2	1
214	Spondyloarthritis: may the force be with you?. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 321-323.	0.5	20
215	TNF-Ĥ inhibitors do not impair sperm quality in males with ankylosing spondylitis after short-term or long-term treatment. <i>Rheumatology</i> , 2014, 53, 1250-1255.	0.9	53
217	RĀ©mission et poussĀ©e dans la spondyloarthrite. <i>Revue Du Rhumatisme Monographies</i> , 2014, 81, 249-252.	0.0	0
218	Construct validity and responsiveness of the simplified version of Ankylosing Spondylitis Disease Activity Score (SASDAS) for the evaluation of disease activity in axial spondyloarthritis. <i>Health and Quality of Life Outcomes</i> , 2014, 12, 129.	1.0	14
219	Etanercept: A Review of Its Use in Autoimmune Inflammatory Diseases. <i>Drugs</i> , 2014, 74, 1379-1410.	4.9	87
220	Unanswered questions in the management of axial spondyloarthritis: an opinion piece. <i>Clinical Rheumatology</i> , 2014, 33, 1359-1365.	1.0	1
225	Effect of aquatic exercise on ankylosing spondylitis: a randomized controlled trial. <i>Rheumatology International</i> , 2014, 34, 1505-1511.	1.5	52
226	Effects of physical therapy for the management of patients with ankylosing spondylitis in the biological era. <i>Clinical Rheumatology</i> , 2014, 33, 1217-1230.	1.0	27
227	Survival of disease-modifying antirheumatic drugs used as the first antirheumatic medication in the treatment of ankylosing spondylitis in Finland. A nationwide population-based register study. <i>Clinical Rheumatology</i> , 2014, 33, 1135-1138.	1.0	6
228	Real-life experience with switching TNF-Ĥ inhibitors in ankylosing spondylitis. <i>European Journal of Health Economics</i> , 2014, 15, 93-100.	1.4	24
229	Recomendaciones para una prescripci3n segura de antiinflamatorios no esteroideos: documento de consenso elaborado por expertos nominados por 3 sociedades cientĀficas (SER-SEC-AEG). <i>ReumatologĀa ClĀnica</i> , 2014, 10, 68-84.	0.2	21
230	Certolizumab Pegol: A Review of Its Use in Patients with Axial Spondyloarthritis or Psoriatic Arthritis. <i>Drugs</i> , 2014, 74, 999-1016.	4.9	12
231	Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 817-823.	0.5	236

#	ARTICLE	IF	CITATIONS
232	Is there a role for sulphasalazine in axial spondyloarthritis in the era of TNF inhibition? Data from the NOR-DMARD longitudinal observational study. <i>Rheumatology</i> , 2014, 53, 1087-1094.	0.9	11
233	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 6-16.	0.5	397
234	Inflammation, new bone formation and treatment options in axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1439-1441.	0.5	12
235	Axial spondyloarthritis. <i>Medicine</i> , 2014, 42, 251-256.	0.2	4
236	Perfil do uso de drogas modificadoras de doena no Registro Brasileiro de Espondiloartrites. <i>Revista Brasileira De Reumatologia</i> , 2014, 54, 33-37.	0.8	4
237	Health-Related Physical Fitness Measures: Reference Values and Reference Equations for Use in Clinical Practice. <i>Archives of Physical Medicine and Rehabilitation</i> , 2014, 95, 1366-1373.	0.5	102
238	Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. <i>Autoimmunity Reviews</i> , 2014, 13, 822-830.	2.5	84
239	Disease burden, disease manifestations and current treatment regimen of the SAPHO syndrome in Germany: Results from a nationwide patient survey. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 745-750.	1.6	46
240	Influence of tumor necrosis factor $\hat{\pm}$ inhibitors on testicular function and semen in spondyloarthritis patients. <i>Fertility and Sterility</i> , 2014, 101, 359-365.	0.5	61
241	ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy. <i>Reumatologa Clnica</i> , 2014, 10, 204-209.	0.2	24
243	Tumor necrosis factor alpha antagonists in the treatment of axial spondyloarthritis. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 647-659.	1.9	22
244	Evidencia cientfica de la rehabilitacin en la espondilitis anquilosante. <i>Rehabilitacion</i> , 2014, 48, 241-249.	0.2	2
246	AB0664Efficacy and Safety of Methylprednisolone Administered Intravenously for the Treatment of Patients with Active Ankylosing Spondylitis: Results of A 12-Week, Prospective, Open-Label Study (METALL): Table 1.. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1024.3-1025.	0.5	0
248	Exercise therapy for ankylosing spondylitis. <i>The Cochrane Library</i> , 0, , .	1.5	3
249	Concurrent Intervention With Exercises and Stabilized Tumor Necrosis Factor Inhibitor Therapy Reduced the Disease Activity in Patients With Ankylosing Spondylitis. <i>Medicine (United States)</i> , 2015, 94, e2254.	0.4	17
251	Axial spondyloarthritis. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15013.	18.1	135
252	Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis. <i>RMD Open</i> , 2015, 1, e000153.	1.8	85
253	Impact on total population health and societal cost, and the implication on the actual cost-effectiveness of including tumour necrosis factor- $\hat{\pm}$ antagonists in management of ankylosing spondylitis: a dynamic population modelling study. <i>Cost Effectiveness and Resource Allocation</i> , 2015, 13, 18.	0.6	4

#	ARTICLE	IF	CITATIONS
254	Barriers and Facilitators for Being Physically Active in Patients with Ankylosing Spondylitis: A Cross-sectional Comparative Study. <i>Musculoskeletal Care</i> , 2015, 13, 76-83.	0.6	33
255	AB0792â€¦Changes in the Metabolism of Hyaluronan Are Associated with Inflammatory Cytokines in Patients with Ankylosing Spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1164.2-1164.	0.5	0
256	Ultrasound-Guided Procedures in Rheumatology. What Is the Evidence?. <i>Journal of Clinical Rheumatology</i> , 2015, 21, 201-210.	0.5	9
257	Periodontitis Response to Anti-TNF Therapy in Ankylosing Spondylitis. <i>Journal of Clinical Rheumatology</i> , 2015, 21, 341-345.	0.5	25
258	Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	1.5	64
259	Reply. <i>Arthritis and Rheumatology</i> , 2015, 67, 2793-2794.	2.9	3
260	Approach to lower back pain. <i>South African Medical Journal</i> , 2015, 105, 1077.	0.2	1
261	Can Whole-Body Cryotherapy with Subsequent Kinesiotherapy Procedures in Closed Type Cryogenic Chamber Improve BASDAI, BASFI, and Some Spine Mobility Parameters and Decrease Pain Intensity in Patients with Ankylosing Spondylitis?. <i>BioMed Research International</i> , 2015, 2015, 1-11.	0.9	41
262	Self management programme for ankylosing spondylitis. <i>The Cochrane Library</i> , 0, , .	1.5	1
263	Ectopic Germinal Centers and IgG4-Producing Plasmacytes Observed in Synovia of HLA-B27+ Ankylosing Spondylitis Patients with Advanced Hip Involvement. <i>International Journal of Rheumatology</i> , 2015, 2015, 1-6.	0.9	6
264	Ankylosing Spondylitis in Association with Non-Hodgkin's Lymphoma : Successful Anti-TNF Alpha Treatment. <i>Journal of Spine</i> , 2015, 04, .	0.2	0
265	Tumor necrosis factor inhibitor therapy in ankylosing spondylitis. <i>Pain</i> , 2015, 156, 297-304.	2.0	47
266	Ultrasound-Guided Interventional Maneuvers. , 2015, , 339-385.		1
267	Management of arthropathy in inflammatory bowel diseases. <i>Therapeutic Advances in Chronic Disease</i> , 2015, 6, 65-77.	1.1	32
268	Pain in systemic inflammatory rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 42-52.	1.4	25
269	Gastrointestinal events in at-risk patients starting non-steroidal anti-inflammatory drugs (NSAIDs) for rheumatic diseases: the EVIDENCE study of European routine practice. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 675-681.	0.5	53
270	Is Etanercept 25 mg Once Weekly as Effective as 50 mg at Maintaining Response in Patients with Ankylosing Spondylitis? A Randomized Control Trial. <i>Journal of Rheumatology</i> , 2015, 42, 1177-1185.	1.0	44
271	The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1373-1378.	0.5	126

#	ARTICLE	IF	CITATIONS
272	Monitoring ankylosing spondylitis: clinically useful markers and prediction of clinical outcomes. Expert Review of Clinical Immunology, 2015, 11, 935-946.	1.3	13
273	The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations: a nationwide register study. Arthritis Research and Therapy, 2015, 17, 118.	1.6	77
275	Effects of Aerobic Training in Patients with Ankylosing Spondylitis. Journal of Rheumatology, 2015, 42, 2347-2353.	1.0	31
276	Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients â€™ baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice. Arthritis Research and Therapy, 2015, 17, 378.	1.6	53
277	Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. New England Journal of Medicine, 2015, 373, 2534-2548.	13.9	803
278	A long-term, observational cohort study on the safety of low-dose glucocorticoids in ankylosing spondylitis: adverse events and effects on bone mineral density, blood lipid and glucose levels and body mass index. BMJ Open, 2015, 5, e006957-e006957.	0.8	15
279	Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies. Therapeutic Advances in Chronic Disease, 2015, 6, 328-338.	1.1	20
280	The prevalence of vertebral fractures in spondyloarthritis: relation to disease characteristics, bone mineral density, syndesmophytes and history of back pain and trauma. Arthritis Research and Therapy, 2015, 17, 294.	1.6	43
281	The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study. Annals of the Rheumatic Diseases, 2015, 74, 970-978.	0.5	69
282	Inflammatory Arthritis in Clinical Practice. , 2015, , .		2
283	Aquatic Exercises were Associated with an Acceptable State of Symptoms in Patients with Inflammatory Rheumatic Diseases: Results from a Study with Interrupted Timeâ€™Series Design. Musculoskeletal Care, 2015, 13, 139-147.	0.6	2
284	Anti-TNFs in axial spondyloarthritis. Wiener Medizinische Wochenschrift, 2015, 165, 10-13.	0.5	1
285	Emerging drugs for the treatment of axial and peripheral spondyloarthritis. Expert Opinion on Emerging Drugs, 2015, 20, 1-14.	1.0	40
286	Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmunity Reviews, 2015, 14, 503-509.	2.5	150
287	Physical activity in spondyloarthritis: a systematic review. Rheumatology International, 2015, 35, 393-404.	1.5	45
289	The potential of selected South African plants with anti-Klebsiella activity for the treatment and prevention of Ankylosing spondylitis. Inflammopharmacology, 2015, 23, 21-35.	1.9	36
290	The impact of ankylosing spondylitis/axial spondyloarthritis on work productivity. Best Practice and Research in Clinical Rheumatology, 2015, 29, 512-523.	1.4	45
291	Factors affecting discontinuation of adalimumab and etanercept therapy in anti-TNF-naïve patients with ankylosing spondylitis: Nationwide population-based cohort study. Modern Rheumatology, 2015, 25, 903-907.	0.9	0

#	ARTICLE	IF	CITATIONS
292	Predictors of Clinical Remission under Anti-tumor Necrosis Factor Treatment in Patients with Ankylosing Spondylitis: Pooled Analysis from Large Randomized Clinical Trials. <i>Journal of Rheumatology</i> , 2015, 42, 1418-1426.	1.0	35
293	Pharmacological therapy of spondyloarthritis. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1495-1504.	0.9	12
294	Male and female patients with axial spondyloarthritis experience disease activity, physical function and quality of life differently: results from the Groningen Leeuwarden Axial Spondyloarthritis cohort: Table 1. <i>Rheumatology</i> , 2015, 54, 1333-1335.	0.9	10
295	Ankilozan spondilitli hastalarda gÃ¼ncel tedavi yaklaÅŸımlarÄ±. <i>Dicle Medical Journal</i> , 2015, 42, .	0.2	2
296	Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice. <i>International Journal of Clinical Pharmacy</i> , 2015, 37, 808-814.	1.0	7
297	The contribution of imaging in the diagnosis and treatment of axial spondyloarthritis. <i>European Journal of Clinical Investigation</i> , 2015, 45, 81-86.	1.7	9
298	Effects of home-based exercise intervention on health-related quality of life for patients with ankylosing spondylitis: a meta-analysis. <i>Clinical Rheumatology</i> , 2015, 34, 1737-1744.	1.0	45
299	Tumour necrosis factor alpha inhibitor therapy and rehabilitation for the treatment of ankylosing spondylitis: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 542-550.	1.6	39
300	Poorer functionality is related to better quality of life response following the use of biological drugs: 6-month outcomes in a prospective cohort from the Public Health System (<i>Sistema ÅŒnico de Tj ETQq0 0.0 rgBT /Qyerlock 10	0.7	11
301	Blocking Interleukin-12 and Interleukin-23 in the Treatment of Axial Spondyloarthritis. <i>Current Treatment Options in Rheumatology</i> , 2015, 1, 231-238.	0.6	0
302	Efficacy of anti-tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta-analysis. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 19.	0.8	27
303	Musculoskeletal Ultrasonography in Rheumatic Diseases. , 2015, , .		5
304	CRP and ASDAS are associated with future elevated arterial stiffness, a risk marker of cardiovascular disease, in patients with ankylosing spondylitis: results after 5-year follow-up. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1562-1566.	0.5	31
305	Conventional DMARDs in axial spondyloarthritis: wishfulâ€”rather than rationalâ€”thinking!. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 951-953.	0.5	7
306	Checklists to manage Pain Induced by Exercise and Mobilization (PIEM) during physical therapy programs: PIEM checklists for practitioners and physiotherapists. <i>Annals of Physical and Rehabilitation Medicine</i> , 2015, 58, 66-73.	1.1	2
307	Inflammatory Bowel Diseases and Spondyloarthropathies. <i>Journal of rheumatology Supplement</i> , The, 2015, 93, 21-23.	2.2	31
308	The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries. <i>Advances in Therapy</i> , 2015, 32, 742-756.	1.3	127
309	Effectiveness and Drug Survival of TNF Inhibitors in the Treatment of Ankylosing Spondylitis: A Prospective Cohort Study. <i>Journal of Rheumatology</i> , 2015, 42, 2339-2346.	1.0	48

#	ARTICLE	IF	CITATIONS
310	In situ analysis of interleukin-6 expression at different sites of zygapophyseal joints from patients with ankylosing spondylitis in comparison to controls. <i>Scandinavian Journal of Rheumatology</i> , 2015, 44, 296-301.	0.6	5
311	Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 166.	0.8	44
312	Clinical characteristics of Japanese patients with axial spondyloarthritis, and short-term efficacy of adalimumab. <i>Journal of Orthopaedic Science</i> , 2015, 20, 1070-1077.	0.5	7
313	Hybrid 18F-labeled Fluoride Positron Emission Tomography/Magnetic Resonance (MR) Imaging of the Sacroiliac Joints and the Spine in Patients with Axial Spondyloarthritis: A Pilot Study Exploring the Link of MR Bone Pathologies and Increased Osteoblastic Activity. <i>Journal of Rheumatology</i> , 2015, 42, 1631-1637.	1.0	48
314	Decreased physical activity and cardiorespiratory fitness in adults with ankylosing spondylitis: a cross-sectional controlled study. <i>Rheumatology International</i> , 2015, 35, 1863-1872.	1.5	38
315	Biologics in spondyloarthritis: TNF α inhibitors and other agents. <i>Immunotherapy</i> , 2015, 7, 669-681.	1.0	14
316	Old and new treatment targets in axial spondyloarthritis. <i>RMD Open</i> , 2015, 1, e000054.	1.8	13
317	Trends in treatment and outcomes of ankylosing spondylitis in outpatient rheumatological care in Germany between 2000 and 2012. <i>RMD Open</i> , 2015, 1, e000033-e000033.	1.8	24
318	Variability in the prescription of non-biologic disease-modifying antirheumatic drugs for the treatment of spondyloarthritis in Spain. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 633-640.	1.6	6
319	Disease-modifying Antirheumatic Drugs (DMARD) and Combination Therapy of Conventional DMARD in Patients with Spondyloarthritis and Psoriatic Arthritis with Axial Involvement. <i>Journal of rheumatology Supplement, The</i> , 2015, 93, 65-69.	2.2	8
320	Remission in Nonradiographic Axial Spondyloarthritis Treated with Anti-tumor Necrosis Factor- α Drugs: An Italian Multicenter Study. <i>Journal of Rheumatology</i> , 2015, 42, 258-263.	1.0	37
321	Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 52-59.	0.5	174
322	Men's Experiences of Living with Ankylosing Spondylitis: A Qualitative Study. <i>Musculoskeletal Care</i> , 2015, 13, 31-41.	0.6	19
323	Responsiveness to therapy change of a global ultrasound assessment in spondyloarthritis patients. <i>Clinical Rheumatology</i> , 2015, 34, 125-132.	1.0	10
324	Biologic Therapy in Inflammatory and Immunomediated Arthritis: Safety Profile. <i>Current Drug Safety</i> , 2016, 11, 22-34.	0.3	8
325	Golimumab in radiographic and nonradiographic axial spondyloarthritis: a review of clinical trials. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 2087-2094.	2.0	3
326	Secukinumab for rheumatology: development and its potential place in therapy. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 2069-2080.	2.0	37
327	Low-dose modified-release prednisone in axial spondyloarthritis: 3-month efficacy and tolerability. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 3717-3724.	2.0	9

#	ARTICLE	IF	CITATIONS
328	Spine and sacroiliac joints on magnetic resonance imaging in patients with early axial spondyloarthritis: prevalence of lesions and association with clinical and disease activity indices from the Italian group of the SPACE study. <i>Reumatismo</i> , 2016, 68, 72-82.	0.4	18
329	Evaluation of a patient decision aid for initiating disease modifying anti-rheumatic drugs. <i>Arthritis Research and Therapy</i> , 2016, 18, 252.	1.6	18
330	Treatment persistence in patients with rheumatoid arthritis and ankylosing spondylitis. <i>Revista De Saude Publica</i> , 2016, 50, 50.	0.7	22
331	Physical Activity in Ankylosing Spondylitis: evaluation and analysis of an eHealth tool. <i>Journal of Innovation in Health Informatics</i> , 2016, 23, 510.	0.9	17
332	Microtrauma. <i>Current Opinion in Rheumatology</i> , 2016, 28, 176-180.	2.0	38
333	The effectiveness of a real life dose reduction strategy for tumour necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis. <i>Rheumatology</i> , 2016, 55, 1837-1842.	0.9	19
334	Review: Enthesitis: New Insights Into Pathogenesis, Diagnostic Modalities, and Treatment. <i>Arthritis and Rheumatology</i> , 2016, 68, 312-322.	2.9	128
335	Continuous Improvement of Physical Functioning in Ankylosing Spondylitis Patients by Tumor Necrosis Factor Inhibitors: Three-Year Followup and Predictors. <i>Arthritis Care and Research</i> , 2016, 68, 1522-1529.	1.5	10
336	MAIT cells: not just another brick in the wall. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 2057-2059.	0.5	16
338	Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. <i>Arthritis Research and Therapy</i> , 2016, 18, 275.	1.6	40
339	Evaluation of the effectiveness of home based or hospital based calisthenic exercises in patients with ankylosing spondylitis. <i>Journal of Back and Musculoskeletal Rehabilitation</i> , 2016, 29, 723-730.	0.4	14
340	Application en région Centre des recommandations nationales et internationales sur l'utilisation des anti-TNF sous-cutanés dans les spondyloarthrites. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2016, 83, A141.	0.0	0
341	Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction. <i>RMD Open</i> , 2016, 2, e000272.	1.8	4
342	Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology. <i>Rheumatology International</i> , 2016, 36, 613-625.	1.5	60
343	Expert Opinion of Spanish Rheumatologists About the Role of Physical Exercise in Ankylosing Spondylitis and Other Rheumatic Diseases. <i>Reumatología Clínica (English Edition)</i> , 2016, 12, 15-21.	0.2	5
344	Indirect and direct costs of treating patients with ankylosing spondylitis in the Brazilian public health system. <i>Revista Brasileira De Reumatologia</i> , 2016, 56, 131-137.	0.7	2
345	Association between arterial stiffness, disease activity and functional impairment in ankylosing spondylitis patients: a cross-sectional study. <i>Clinical Rheumatology</i> , 2016, 35, 2017-2022.	1.0	11
346	New evidence on the management of spondyloarthritis. <i>Nature Reviews Rheumatology</i> , 2016, 12, 282-295.	3.5	104

#	ARTICLE	IF	CITATIONS
348	Assessment of clinical efficacy and safety in a randomized double-blind study of etanercept and sulfasalazine in patients with ankylosing spondylitis from Eastern/Central Europe, Latin America, and Asia. <i>Rheumatology International</i> , 2016, 36, 643-651.	1.5	12
349	Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. <i>Arthritis Research and Therapy</i> , 2016, 18, 25.	1.6	120
350	The effect of total hip replacement on employment in patients with ankylosing spondylitis. <i>Clinical Rheumatology</i> , 2016, 35, 2975-2981.	1.0	15
351	Physical activity in patients with axial spondyloarthritis: a cross-sectional study of 203 patients. <i>Rheumatology International</i> , 2016, 36, 1711-1718.	1.5	27
352	THREE-DIMENSIONAL GAIT ANALYSIS AS A POTENTIAL AND QUANTIFIABLE MEASUREMENT IN THE CLINICAL EVALUATION OF ANKYLOSING SPONDYLITIS. <i>Journal of Mechanics in Medicine and Biology</i> , 2016, 16, 1650001.	0.3	1
353	Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art. <i>Clinical Rheumatology</i> , 2016, 35, 2631-2638.	1.0	28
355	Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases. <i>BioDrugs</i> , 2016, 30, 607-617.	2.2	30
356	Physical Activity and Exercise: Perspectives of Adults With Ankylosing Spondylitis. <i>Journal of Physical Activity and Health</i> , 2016, 13, 504-513.	1.0	34
357	Inflammation chronique de l'intestin et rhumatismes inflammatoires (maladie de Crohn, RCH, maladie) Tj ETQq0.0 rgBT4/Overlock		
358	American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. <i>Arthritis Care and Research</i> , 2016, 68, 151-166.	1.5	53
359	American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 282-298.	2.9	383
360	Etanercept (SB4): A Review in Autoimmune Inflammatory Diseases. <i>BioDrugs</i> , 2016, 30, 371-378.	2.2	13
361	Rheumatoid Arthritis and Spondyloarthritis. , 2016, , 181-215.		0
363	PROMs and Patient Education. , 2016, , 389-403.		2
364	Centre characteristics determine ambulatory care and referrals in patients with spondyloarthritis. <i>Rheumatology International</i> , 2016, 36, 1515-1523.	1.5	1
365	Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases. <i>BioDrugs</i> , 2016, 30, 469-480.	2.2	22
367	Effect of Secukinumab on Patient-Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1). <i>Arthritis and Rheumatology</i> , 2016, 68, 2901-2910.	2.9	63
368	New targets in psoriatic arthritis. <i>Rheumatology</i> , 2016, 55, ii30-ii37.	0.9	14

#	ARTICLE	IF	CITATIONS
369	Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. <i>Nature Reviews Rheumatology</i> , 2016, 12, 743-750.	3.5	71
370	Vasculitis and inflammatory arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 916-931.	1.4	16
371	A randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib versus naproxen in patients with ankylosing spondylitis. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 426.	0.8	22
372	Costs of Drug Therapy in Patients with Ankylosing Spondylitis in Brazil. <i>Rheumatology and Therapy</i> , 2016, 3, 353-361.	1.1	5
373	AB1095-HPR...Evaluation of The Static Foot Function in Patients with Reduced Mobility in The Course of Rheumatic Diseases. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1306.2-1306.	0.5	0
374	The Burden of Rheumatic Diseases: An Analysis of an Italian Administrative Database. <i>Rheumatology and Therapy</i> , 2016, 3, 167-177.	1.1	5
375	Sleep Quality Is Related to Disease Activity in Patients With Ankylosing Spondylitis. <i>Journal of Clinical Rheumatology</i> , 2016, 22, 248-252.	0.5	13
376	Secukinumab: A Review in Ankylosing Spondylitis. <i>Drugs</i> , 2016, 76, 1023-1030.	4.9	35
378	Real Life Experience of First Course of Anti-TNF Treatment in Ankylosing Spondylitis Patients in Brazil. <i>Rheumatology and Therapy</i> , 2016, 3, 143-154.	1.1	4
379	Ankylosing spondylitis self-help organisations – Do members differ from non-members?. <i>Joint Bone Spine</i> , 2016, 83, 295-300.	0.8	4
380	Cross-cultural adaptation and validation of the Portuguese version of “The assessment of knowledge in ankylosing spondylitis patients by a self-administered questionnaire” <i>Rheumatology International</i> , 2016, 36, 515-519.	1.5	5
382	Ankylosing Spondylitis and Axial Spondyloarthritis. <i>New England Journal of Medicine</i> , 2016, 374, 2563-2574.	13.9	565
383	Impact of peer-led group education on the quality of life in patients with ankylosing spondylitis. <i>International Journal of Rheumatic Diseases</i> , 2016, 19, 184-191.	0.9	10
384	Histopathological changes in supraspinous ligaments, ligamentum flava and paraspinal muscle tissues of patients with ankylosing spondylitis. <i>International Journal of Rheumatic Diseases</i> , 2016, 19, 420-429.	0.9	26
385	Impact of a multidisciplinary approach in enteropathic spondyloarthritis patients. <i>Autoimmunity Reviews</i> , 2016, 15, 184-190.	2.5	39
386	Golimumab for treatment of axial spondyloarthritis. <i>Immunotherapy</i> , 2016, 8, 107-115.	1.0	1
387	Challenges of diagnosis and management of axial spondyloarthritis in North Africa and the Middle East: An expert consensus. <i>Journal of International Medical Research</i> , 2016, 44, 216-230.	0.4	13
388	Development of System-level Performance Measures for Evaluation of Models of Care for Inflammatory Arthritis in Canada. <i>Journal of Rheumatology</i> , 2016, 43, 530-540.	1.0	63

#	ARTICLE	IF	CITATIONS
389	Healthcare Resource Use and Direct Costs in Patients with Ankylosing Spondylitis and Psoriatic Arthritis in a Large US Cohort. <i>Journal of Rheumatology</i> , 2016, 43, 88-96.	1.0	32
390	Secukinumab (AIN457) in the treatment of ankylosing spondylitis. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 711-722.	1.4	22
391	Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients. <i>Journal of International Medical Research</i> , 2016, 44, 483-495.	0.4	18
392	Ankylosing spondylitis diagnosis in US patients with back pain: identifying providers involved and factors associated with rheumatology referral delay. <i>Clinical Rheumatology</i> , 2016, 35, 1769-1776.	1.0	72
393	Atherosclerotic cardiovascular disease in patients with chronic inflammatory joint disorders. <i>Heart</i> , 2016, 102, 790-795.	1.2	79
394	Nonsteroidal Antiinflammatory Drugs for Axial Spondyloarthritis: A Cochrane Review. <i>Journal of Rheumatology</i> , 2016, 43, 607-617.	1.0	32
395	Investigating the effects of a multidimensional exercise program on symptoms and antiinflammatory status in female patients with ankylosing spondylitis. <i>Complementary Therapies in Clinical Practice</i> , 2016, 22, 38-43.	0.7	14
396	Etanercept for the treatment of non-radiographic axial spondyloarthritis. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 493-500.	1.3	2
397	NSAIDs in axial spondyloarthritis: to be continued? <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1423-1425.	0.5	6
398	Utility of the pedicle subtraction osteotomy for the correction of sagittal spine imbalance. <i>International Orthopaedics</i> , 2016, 40, 1219-1225.	0.9	13
399	Effectiveness of ultrasound treatment applied with exercise therapy on patients with ankylosing spondylitis: a double-blind, randomized, placebo-controlled trial. <i>Rheumatology International</i> , 2016, 36, 653-661.	1.5	21
400	Effects of tumor necrosis factor- α inhibitors on new bone formation in ankylosing spondylitis. <i>Joint Bone Spine</i> , 2016, 83, 257-264.	0.8	17
401	Favorable effect of rehabilitation on balance in ankylosing spondylitis: a quasi-randomized controlled clinical trial. <i>Rheumatology International</i> , 2016, 36, 333-339.	1.5	16
402	Custos diretos e indiretos do tratamento de pacientes com espondilite anquilosante pelo sistema p�blico de sa�de brasileiro. <i>Revista Brasileira De Reumatologia</i> , 2016, 56, 131-137.	0.8	5
403	The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 239-254.	0.6	577
404	An overview of investigational new drugs for treating ankylosing spondylitis. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 95-104.	1.9	14
405	Measurable definitions of ankylosing spondylitis management recommendations are needed for use in observational studies. <i>Joint Bone Spine</i> , 2016, 83, 101-103.	0.8	5
406	Opini�n de los reumat�logos espa�oles expertos en espondiloartritis sobre el papel del ejercicio en la espondilitis anquilosante y otras enfermedades reum�ticas. <i>Reumatolog�a Cl�nica</i> , 2016, 12, 15-21.	0.2	8

#	ARTICLE	IF	CITATIONS
407	Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 519-532.	1.6	45
408	Remission in axial spondyloarthritis: The ultimate treatment goal?. <i>Joint Bone Spine</i> , 2016, 83, 117-119.	0.8	10
410	Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany. <i>Rheumatology International</i> , 2016, 36, 143-153.	1.5	22
411	Use of biologics in SLE: a review of the evidence from a clinical perspective. <i>Rheumatology</i> , 2016, 55, 775-779.	0.9	10
412	Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2â€¦years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1438-1443.	0.5	163
413	Decreased health-related physical fitness in adults with ankylosing spondylitis: a cross-sectional controlled study. <i>Physiotherapy</i> , 2016, 102, 202-209.	0.2	18
414	Rituximab therapy for ankylosing spondylitis associated to demyelinating disease of the central nervous system. <i>Joint Bone Spine</i> , 2016, 83, 105-106.	0.8	4
415	A multicenter, open-label, long-term study of three-year infliximab administration in Japanese patients with ankylosing spondylitis. <i>Modern Rheumatology</i> , 2017, 27, 142-149.	0.9	7
416	Use of nonsteroidal anti-inflammatory drugs in early axial spondyloarthritis in daily practice: Data from the DESIR cohort. <i>Joint Bone Spine</i> , 2017, 84, 79-82.	0.8	9
417	Barreras y facilitadores para la prÃ¡ctica del ejercicio fÃ­sico en pacientes con espondiloartritis: estudio cualitativo de grupos focales (EJES-3D). <i>ReumatologÃ­a ClÃ­nica</i> , 2017, 13, 91-96.	0.2	10
418	New treatment options and emerging drugs for axial spondyloarthritis: biological and targeted synthetic agents. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 275-282.	0.9	8
419	Higher body mass index and anti-drug antibodies predict the discontinuation of anti-TNF agents in Korean patients with axial spondyloarthritis. <i>Revista Brasileira De Reumatologia</i> , 2017, 57, 311-319.	0.7	3
420	Recomendaciones del Grupo EspaÃ±ol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el tratamiento de pacientes con espondiloartritis asociada a enfermedad inflamatoria intestinal. <i>Enfermedad Inflamatoria Intestinal Al DÃ­a</i> , 2017, 16, 1-14.	0.2	0
421	The association of <i>NLRP3</i> and <i>TNFRSF1A</i> polymorphisms with risk of ankylosing spondylitis and treatment efficacy of etanercept. <i>Journal of Clinical Laboratory Analysis</i> , 2017, 31, .	0.9	26
422	Should axial spondyloarthritis without radiographic changes be treated with anti-TNF agents?. <i>Rheumatology International</i> , 2017, 37, 327-336.	1.5	9
423	Work disability in non-radiographic axial spondyloarthritis patients before and after start of anti-TNF therapy: a population-based regional cohort study from southern Sweden. <i>Rheumatology</i> , 2017, 56, kew473.	0.9	6
425	Therapies of Early, Advanced, and Late Onset Forms of Axial Spondyloarthritis, and the Need for Treat to Target Strategies. <i>Current Rheumatology Reports</i> , 2017, 19, 8.	2.1	8
426	Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1070-1077.	0.5	213

#	ARTICLE	IF	CITATIONS
427	Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1340-1347.	0.5	287
428	Secukinumab efficacy in anti-TNF-naïve and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 571-592.	0.5	137
429	Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study. <i>Arthritis Care and Research</i> , 2017, 69, 1020-1029.	1.5	79
431	2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 978-991.	0.5	1,220
432	IgA-coated <i>E. coli</i> enriched in Crohn's disease spondyloarthritis promote T _H 17-dependent inflammation. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	246
433	Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. <i>RMD Open</i> , 2017, 3, e000396.	1.8	99
434	Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. <i>RMD Open</i> , 2017, 3, e000397.	1.8	69
435	Dosing down with biologic therapies: a systematic review and clinicians' perspective. <i>Rheumatology</i> , 2017, 56, 1847-1856.	0.9	59
436	Effects of Long-Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104-Week Results From a Randomized, Placebo-Controlled Study. <i>Arthritis Care and Research</i> , 2017, 69, 1590-1598.	1.5	28
437	Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 343-350.	1.6	68
438	Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry. <i>Journal of Rheumatology</i> , 2017, 44, 59-69.	1.0	45
439	Association of HLA-B27 with ankylosing spondylitis and clinical features of the HLA-B27-associated ankylosing spondylitis: a meta-analysis. <i>Rheumatology International</i> , 2017, 37, 1267-1280.	1.5	32
440	Golimumab: A Review in Inflammatory Arthritis. <i>BioDrugs</i> , 2017, 31, 263-274.	2.2	11
442	Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 589-596.	0.9	28
443	Occupational driving assessment for late-stage ankylosing spondylitis. <i>Rheumatology International</i> , 2017, 37, 1599-1600.	1.5	0
444	Treat to Target in Axial Spondyloarthritis: What Are the Issues?. <i>Current Rheumatology Reports</i> , 2017, 19, 22.	2.1	17
445	Exercise and physical activity in systemic lupus erythematosus: A systematic review with meta-analyses. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 204-215.	1.6	93
446	Exploring the relationship between demographic and disease-related variables and perceived effect of health status on sexual activity in patients with axial spondyloarthritis: associations found only with non-disease variables. <i>Scandinavian Journal of Rheumatology</i> , 2017, 46, 461-467.	0.6	14

#	ARTICLE	IF	CITATIONS
447	Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 183-192.	1.6	63
448	Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients. <i>Arthritis Research and Therapy</i> , 2017, 19, 64.	1.6	81
449	Associations de patients atteints de spondylarthrite ankylosante – Quelles différences entre membres et non-membres?. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2017, 84, 231-237.	0.0	0
450	Ultrasound Evaluation of the Entheses in Daily Clinical Practice during Tumor Necrosis Factor- β Blocking Therapy in Patients with Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2017, 44, 587-593.	1.0	11
451	Barriers and Facilitators for the Practice of Physical Exercise in Patients With Spondyloarthritis: Qualitative Study of Focus Groups (EJES-3D). <i>Reumatologia Clínica (English Edition)</i> , 2017, 13, 91-96.	0.2	7
452	Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis. <i>Rheumatology</i> , 2017, 56, 95-102.	0.9	58
453	EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 17-28.	0.5	918
454	O maior Índice de massa corporal e a presença de anticorpos anti- γ rmacos predizem a interrupção no uso de agentes anti-TNF em pacientes sul-coreanos com espondiloartrite axial. <i>Revista Brasileira De Reumatologia</i> , 2017, 57, 311-319.	0.8	8
455	Behaviour change intervention increases physical activity, spinal mobility and quality of life in adults with ankylosing spondylitis: a randomised trial. <i>Journal of Physiotherapy</i> , 2017, 63, 30-39.	0.7	27
456	Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm. <i>Rheumatology</i> , 2017, 56, iv30-iv48.	0.9	32
459	Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitors. <i>Rheumatology International</i> , 2017, 37, 2049-2058.	1.5	13
460	Patient Burden of Axial Spondyloarthritis. <i>Journal of Clinical Rheumatology</i> , 2017, 23, 383-391.	0.5	85
461	Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results. <i>Rheumatology</i> , 2017, 56, 1771-1779.	0.9	49
462	The Duality of Economic Issues With Medication Non-adherence in Patients With Inflammatory Arthritis. <i>Current Rheumatology Reports</i> , 2017, 19, 66.	2.1	8
465	Arthropathies in Inflammatory Bowel Disease. <i>Gastroenterology Nursing</i> , 2017, 40, 496-503.	0.2	1
469	Entzündlicher Rückenschmerz – sind Warnsignalisten verlässlich?. <i>Osteopathische Medizin</i> , 2017, 18, 26-32.	0.2	0
470	TNF-blockers followed by continuation of sulfasalazine and methotrexate combination: a retrospective study on cost saving options of treatment in Spondyloarthritis. <i>Clinical Rheumatology</i> , 2017, 36, 2243-2251.	1.0	5
471	National variation in the composition of rheumatology multidisciplinary teams: a cross-sectional study. <i>Rheumatology International</i> , 2017, 37, 1453-1459.	1.5	23

#	ARTICLE	IF	CITATIONS
473	Development of a web-based patient decision aid for initiating disease modifying anti-rheumatic drugs using user-centred design methods. <i>BMC Medical Informatics and Decision Making</i> , 2017, 17, 51.	1.5	21
474	Multidisciplinary management of patients with coexisting inflammatory bowel disease and spondyloarthritis: A Delphi consensus among Italian experts. <i>Digestive and Liver Disease</i> , 2017, 49, 1298-1305.	0.4	13
475	Adherence to Antitumor Necrosis Factor Use Recommendations in Spondyloarthritis: Measurement and Effect in the DESIR Cohort. <i>Journal of Rheumatology</i> , 2017, 44, 1436-1444.	1.0	1
476	Golimumab for the treatment of axial spondyloarthritis. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 129-133.	1.4	3
477	Remission is related to CRP and smoking in early axial spondyloarthritis. The DESIR cohort. <i>Joint Bone Spine</i> , 2017, 84, 473-476.	0.8	14
478	Treatment patterns, complications, and direct medical costs associated with ankylosing spondylitis in Chinese urban patients: a retrospective claims dataset analysis. <i>Journal of Medical Economics</i> , 2017, 20, 91-97.	1.0	6
480	Clinical Risk Factors for the Presence and Development of Vertebral Fractures in Patients With Ankylosing Spondylitis. <i>Arthritis Care and Research</i> , 2017, 69, 694-702.	1.5	36
481	Systematic review of clinical, humanistic, and economic outcome comparisons between radiographic and non-radiographic axial spondyloarthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 746-753.	1.6	29
482	Certolizumab pegol administration devices: a profile of their use and usability. <i>Drugs and Therapy Perspectives</i> , 2017, 33, 515-522.	0.3	5
483	Educational needs in patients with spondyloarthritis in Sweden – a mixed-methods study. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 335.	0.8	17
484	Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel. <i>Frontiers in Pharmacology</i> , 2017, 8, 322.	1.6	21
485	Diagnosis and Treatment of Inflammatory Joint Disease. <i>Hip and Pelvis</i> , 2017, 29, 211.	0.6	39
486	A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 1969-1978.	2.0	11
487	Disease activity in axial spondyloarthritis after discontinuation of TNF inhibitors therapy. <i>Reumatologia</i> , 2017, 4, 157-162.	0.5	14
488	Anti-IL17A in Axial Spondyloarthritis – Where Are We At?. <i>Frontiers in Medicine</i> , 2017, 4, 1.	1.2	60
489	Comparison of Deep Tissue Massage and Therapeutic Massage for Lower Back Pain, Disease Activity, and Functional Capacity of Ankylosing Spondylitis Patients: A Randomized Clinical Pilot Study. <i>Evidence-based Complementary and Alternative Medicine</i> , 2017, 2017, 1-7.	0.5	15
490	Coexistence of Peripheral Spondyloarthritis and Familial Adenomatous Polyposis: A Rare Case Report with Treatment Contradictions and Review of the Literature. <i>Ethiopian Journal of Health Sciences</i> , 2017, 27, 441.	0.2	1
491	Are Systematic Screening for Vitamin D Deficiency and Vitamin D Supplementation Currently Feasible for Ankylosing Spondylitis Patients?. <i>International Journal of Inflammation</i> , 2017, 2017, 1-10.	0.9	6

#	ARTICLE	IF	CITATIONS
492	Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics. <i>Mediators of Inflammation</i> , 2017, 2017, 1-15.	1.4	93
494	Association between circulating miRNAs and spinal involvement in patients with axial spondyloarthritis. <i>PLoS ONE</i> , 2017, 12, e0185323.	1.1	30
495	The relationship between demographic- and disease-related variables and health-related quality of life in patients with axial spondyloarthritis. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 328.	0.8	20
496	Adaptation of Chinese and English versions of the Ankylosing Spondylitis quality of life (ASQoL) scale for use in Singapore. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 353.	0.8	14
497	Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. <i>Arthritis Research and Therapy</i> , 2017, 19, 285.	1.6	161
498	Do biological disease-modifying antirheumatic drugs reduce the spinal fracture risk related to ankylosing spondylitis? A longitudinal multiregistry matched cohort study. <i>BMJ Open</i> , 2017, 7, e016548.	0.8	0
499	The immune dysfunction in ankylosing spondylitis patients. <i>BioScience Trends</i> , 2017, 11, 69-76.	1.1	21
500	Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 95-106.	0.8	15
501	Relationship between kinesiphobia and pain, quality of life, functional status, disease activity, mobility, and depression in patients with ankylosing spondylitis. <i>Turkish Journal of Medical Sciences</i> , 2017, 47, 1340-1347.	0.4	26
502	Gene Expression Analysis before and after Treatment with Adalimumab in Patients with Ankylosing Spondylitis Identifies Molecular Pathways Associated with Response to Therapy. <i>Genes</i> , 2017, 8, 127.	1.0	11
503	Comparative Efficacy and Safety of Secukinumab and Adalimumab in Patients with Active Ankylosing Spondylitis: A Bayesian Network Meta-analysis of Randomized Controlled Trials. <i>Journal of Rheumatic Diseases</i> , 2017, 24, 211.	0.4	16
504	Spondyloarthritides. , 2017, , 189-211.		0
505	Risk of myocardial infarction with use of selected non-steroidal anti-inflammatory drugs in patients with spondyloarthritis and osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2018-213089.	0.5	38
506	Patients with spondyloarthritis are equally satisfied with follow-up by physiotherapist and rheumatologist. <i>Musculoskeletal Care</i> , 2018, 16, 388-397.	0.6	4
507	Cost-effectiveness Analysis of Golimumab in the Treatment of Non-Radiographic Axial Spondyloarthritis in Scotland. <i>Rheumatology and Therapy</i> , 2018, 5, 57-73.	1.1	1
508	Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing) Tj ETQq1 1 0.784314 rgBT /Overlook subcutaneous TNF inhibitors. <i>Clinical Rheumatology</i> , 2018, 37, 1617-1623.	1.0	12
509	Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence. <i>Journal of Rheumatology</i> , 2018, 45, 785-794.	1.0	43
510	Quality of Care in Rheumatoid Disease from the Clinician Perspective: A Modified Delphi Panel Approach. <i>Rheumatology and Therapy</i> , 2018, 5, 87-98.	1.1	1

#	ARTICLE	IF	CITATIONS
511	Physical activity behaviour in men with inflammatory joint disease: a cross-sectional register-based study. <i>Rheumatology</i> , 2018, 57, 803-812.	0.9	8
512	Characterization of Patients With Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis in the <sc>US</sc>â€Based Corrona Registry. <i>Arthritis Care and Research</i> , 2018, 70, 1661-1670.	1.5	53
513	Application of Recommendations Regarding the Use of Subcutaneous Tumor Necrosis Factor Inhibitors in Spondyloarthritis by Rheumatologists in Daily Practice. <i>Journal of Rheumatology</i> , 2018, 45, 491-497.	1.0	2
514	Standards of care and quality indicators for multidisciplinary care models for psoriatic arthritis in Spain. <i>Rheumatology International</i> , 2018, 38, 1115-1124.	1.5	14
515	Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study. <i>Rheumatology</i> , 2018, 57, 688-693.	0.9	33
516	Enthesopathy in rheumatoid arthritis and spondyloarthritis: An ultrasound study. <i>Joint Bone Spine</i> , 2018, 85, 577-581.	0.8	12
517	An open label clinical trial of thalidomide in NSAIDs refractory ankylosing spondylitis. <i>Modern Rheumatology</i> , 2018, 28, 730-732.	0.9	2
518	Risk of serious infections in biological treatment of patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. <i>Clinical Rheumatology</i> , 2018, 37, 439-450.	1.0	15
519	Novel Therapeutic Targets in Axial Spondyloarthritis. <i>Current Treatment Options in Rheumatology</i> , 2018, 4, 174-182.	0.6	8
520	Efficacy of long-term nonsteroidal antiinflammatory drug treatment on magnetic resonance imaging-determined bone marrow oedema in early, active axial spondyloarthritis patients. <i>Clinical Rheumatology</i> , 2018, 37, 245-250.	1.0	6
521	Evaluation of sleep quality in patients with ankylosing spondylitis and efficacy of antiâ€<sc>TNF</sc>â€™± therapy on sleep problems: A polysomnographic study. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 1263-1269.	0.9	17
522	Faecal calprotectin detects subclinical bowel inflammation and may predict treatment response in spondyloarthritis. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 48-55.	0.6	30
523	Comparison of drug survival and clinical outcome in patients with ankylosing spondylitis treated with etanercept or adalimumab. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 122-126.	0.6	10
524	A randomized controlled trial to study the efficacy of sulfasalazine for axial disease in ankylosing spondylitis. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 308-314.	0.9	28
525	La rÃ©mission est associÃ©e Ã la CRP et au tabagisme dans la spondyloarthrite axiale dÃ©butante. La cohorte DESIR. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2018, 85, 178-182.	0.0	0
526	Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs. <i>Joint Bone Spine</i> , 2018, 85, 455-459.	0.8	14
527	Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited. <i>Postgraduate Medicine</i> , 2018, 130, 55-71.	0.9	46
528	Clinical and ultrasonographic enthesopathy in inflammatory rheumatic diseases. <i>Zeitschrift Fur Rheumatologie</i> , 2018, 77, 719-726.	0.5	4

#	ARTICLE	IF	CITATIONS
529	Evaluation of the efficacy and safety of Î²-d-mannuronic acid in patients with ankylosing spondylitis: A 12-week randomized, placebo-controlled, phase I/II clinical trial. <i>International Immunopharmacology</i> , 2018, 54, 112-117.	1.7	26
530	Managing morbidity and treatment-related toxicity in patients with ankylosing spondylitis. <i>Rheumatology</i> , 2018, 57, 419-428.	0.9	11
531	Hemoglobin A1c, Not Glycated Albumin, Can Independently Reflect the Ankylosing Spondylitis Disease Activity Score. <i>Journal of Rheumatic Diseases</i> , 2018, 25, 131.	0.4	2
532	Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies. <i>RMD Open</i> , 2018, 4, e000749.	1.8	30
533	Disease modification in axial spondyloarthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 427-439.	1.4	10
534	The comparative efficacy of group- versus home-based exercise programs in patients with ankylosing spondylitis. <i>Medicine (United States)</i> , 2018, 97, e11540.	0.4	2
535	Advances in understanding the pathophysiology of spondyloarthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 331-341.	1.4	23
536	Where Have All the Patients Gone? Profile of US Adults Who Report Doctor-Diagnosed Arthritis But Are Not Being Treated. <i>Journal of Clinical Rheumatology</i> , 2019, 25, 341-347.	0.5	6
538	Patient-reported outcomes in European spondyloarthritis patients: a systematic review of the literature. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 733-747.	0.8	18
539	Radiographic Progression in Ankylosing Spondylitis: From Prognostication to Disease Modification. <i>Current Rheumatology Reports</i> , 2018, 20, 82.	2.1	18
540	The current standard of care and the unmet needs for axial spondyloarthritis. <i>Rheumatology</i> , 2018, 57, vi10-vi17.	0.9	19
541	Effects of global postural reeducation exercise and anti-TNF treatments on disease activity, function, fatigue, mobility, sleep quality and depression in patients with active Ankylosing spondylitis: A prospective follow-up study. <i>Journal of Back and Musculoskeletal Rehabilitation</i> , 2018, 31, 1005-1012.	0.4	10
542	The role of secukinumab in the treatment of psoriatic arthritis and ankylosing spondylitis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2018, 10, 169-180.	1.2	16
543	High Rate of Drug-Free Remission After Induction Therapy With Golimumab in Early Peripheral Spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1769-1777.	2.9	15
544	Rheumatologic Rehabilitation. , 2018, , 208-213.e3.		1
545	Diagnostic value of salivary CRP and IL-6 in patients undergoing anti-TNF-alpha therapy for rheumatic disease. <i>Inflammopharmacology</i> , 2018, 26, 1183-1188.	1.9	14
546	Simplified Chinese version of hip and knee replacement expectations surveys in patients with osteoarthritis and ankylosing spondylitis: cross-cultural adaptation, validation and reliability. <i>BMC Musculoskeletal Disorders</i> , 2018, 19, 247.	0.8	7
547	Preventive effect of tumor necrosis factor inhibitors versus nonsteroidal anti-inflammatory drugs on uveitis in patients with ankylosing spondylitis. <i>Clinical Rheumatology</i> , 2018, 37, 2763-2770.	1.0	4

#	ARTICLE	IF	CITATIONS
548	The impact of non-persistence on the direct and indirect costs in patients treated with subcutaneous tumour necrosis factor-alpha inhibitors in Germany. <i>Rheumatology</i> , 2018, 57, 1276-1281.	0.9	7
549	Cupping therapy for treating ankylosing spondylitis: The evidence from systematic review and meta-analysis. <i>Complementary Therapies in Clinical Practice</i> , 2018, 32, 187-194.	0.7	13
551	Personalized Axial Spondyloarthritis Care. <i>Current Treatment Options in Rheumatology</i> , 2018, 4, 158-173.	0.6	1
552	Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison. <i>Nature Reviews Rheumatology</i> , 2018, 14, 363-371.	3.5	149
553	Efficacy and Safety of Secukinumab 150mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study. <i>Rheumatology and Therapy</i> , 2018, 5, 447-462.	1.1	73
554	Cupping therapy for treating ankylosing spondylitis: Protocol for a systematic review. <i>European Journal of Integrative Medicine</i> , 2018, 21, 34-38.	0.8	1
555	Development and application of a questionnaire to assess patient beliefs in rheumatoid arthritis and axial spondyloarthritis. <i>Clinical Rheumatology</i> , 2018, 37, 2649-2657.	1.0	13
556	Sacroiliac joints: anatomical variations on MR images. <i>European Radiology</i> , 2018, 28, 5328-5337.	2.3	33
557	Inflammatory or Neuropathic Pain: Characteristics and Their Relationships with Disease Activity and Functional Status in Axial Spondyloarthritis Patients. <i>Pain Medicine</i> , 2019, 20, 882-888.	0.9	9
558	Association between use of non-steroidal anti-inflammatory drugs and risk of myocardial infarction in patients with spondyloarthritis and osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e78-e78.	0.5	8
559	Factors Associated With Initiation of Biologics in Patients With Axial Spondyloarthritis in an Urban Asian City. <i>Journal of Clinical Rheumatology</i> , 2019, 25, 59-64.	0.5	7
560	Multimodal analgesia to reduce NSAID induced myocardial infarction. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e87-e87.	0.5	0
561	The value of contrast-enhanced ultrasonography to detect the sacroiliac joint for predicting relapse after discontinuation of anti-tumor necrosis factor therapy in patients with ankylosing spondylitis. <i>Quantitative Imaging in Medicine and Surgery</i> , 2019, 9, 1110-1117.	1.1	3
562	Moxibustion therapy in Chinese patients with ankylosing spondylitis: A randomized controlled pilot trial. <i>European Journal of Integrative Medicine</i> , 2019, 31, 100952.	0.8	4
563	Living with ankylosing spondylitis: an open response survey exploring physical activity experiences. <i>Rheumatology Advances in Practice</i> , 2019, 3, rkz016.	0.3	5
564	Disease Activity, Occupational Participation, and Quality of Life for Individuals with and without Severe Fatigue in Ankylosing Spondylitis. <i>Occupational Therapy International</i> , 2019, 2019, 1-10.	0.3	16
565	The reliability and validity of a Venezuelan version of the Bath Ankylosing Spondylitis Functional Index (BASFI) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). <i>Reumatología Clínica (English Edition)</i> , 2019, 15, 223-228.	0.2	2
566	The impact of sex and disease classification on patient-reported outcome measures in axial spondyloarthritis: a descriptive prospective cross-sectional study. <i>Arthritis Research and Therapy</i> , 2019, 21, 221.	1.6	11

#	ARTICLE	IF	CITATIONS
567	The perspective of people with axial spondyloarthritis regarding physiotherapy: room for the implementation of a more active approach. <i>Rheumatology Advances in Practice</i> , 0, , .	0.3	5
568	Serological Biomarkers in Early Axial Spondyloarthritis During 24-Months Follow Up (Italian Arm of) Tj ETQq1 1 0.784314 rgBTj /Overlo	1.2	9
569	Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1536-1544.	0.5	58
570	Vaccination status of patients using anti-TNF therapy and the physicians' behavior shaping the phenomenon: Mixed-methods approach. <i>PLoS ONE</i> , 2019, 14, e0223594.	1.1	8
571	Drug maintenance of a second tumor necrosis factor alpha inhibitor in spondyloarthritis patients: A real-life multicenter study. <i>Joint Bone Spine</i> , 2019, 86, 761-767.	0.8	6
572	Long-Term Treatment With TNF-Alpha Inhibitors Improves Bone Mineral Density But Not Vertebral Fracture Progression in Ankylosing Spondylitis. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 1041-1048.	3.1	26
573	Targeting inflammatory pathways in axial spondyloarthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 135.	1.6	27
574	A Pilot Study to Assess the Feasibility of a Web-Based Survey to Examine Patient-Reported Symptoms and Satisfaction in Patients with Ankylosing Spondylitis Receiving Secukinumab. <i>Drugs - Real World Outcomes</i> , 2019, 6, 83-91.	0.7	5
575	Extraarticular Manifestations. , 2019, , 157-182.		14
576	Nonpharmacologic Management of Axial Spondyloarthritis. , 2019, , 203-216.		1
577	Treatment Guidelines for Axial Spondyloarthritis. , 2019, , 243-258.		0
578	Unmet needs in the treatment of ankylosing spondylitis: a long-term observational study from a single university center. <i>Rheumatology International</i> , 2019, 39, 663-668.	1.5	1
579	Comparaison de l'Échographie des enthèses dans la polyarthrite rhumatoïde et la spondyloarthrite. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2019, 86, 269-274.	0.0	2
580	Effects of Multidisciplinary Team-Based Nurse-led Transitional Care on Clinical Outcomes and Quality of Life in Patients With Ankylosing Spondylitis. <i>Asian Nursing Research</i> , 2019, 13, 107-114.	0.7	12
581	A prospective clinical investigation of the effects of anti-TNF alpha therapy on exercise capacity in patients with ankylosing spondylitis. <i>Turkish Journal of Medical Sciences</i> , 2019, 49, 27-32.	0.4	2
582	Moxibustion intervention for patients with ankylosing spondylitis: A study Protocol for a pilot randomized controlled trial. <i>European Journal of Integrative Medicine</i> , 2019, 27, 18-26.	0.8	3
583	Development of generic core competences of health professionals in rheumatology: a systematic literature review informing the 2019 EULAR recommendations. <i>RMD Open</i> , 2019, 5, e001028.	1.8	1
584	A systematic review of the factors associated with the initiation of biologicals in patients with rheumatological conditions. <i>European Journal of Hospital Pharmacy</i> , 2019, 26, 163-169.	0.5	4

#	ARTICLE	IF	CITATIONS
585	Exercise programmes for ankylosing spondylitis. The Cochrane Library, 2019, 10, CD011321.	1.5	31
586	Two-Level Osteotomy for the Corrective Surgery of Severe Kyphosis From Ankylosing Spondylitis. Spine, 2019, 44, 1638-1646.	1.0	21
587	Aerobic exercise for axial spondyloarthritis –its effects on disease activity and function as compared to standard physiotherapy: A systematic review and meta-analysis. International Journal of Rheumatic Diseases, 2019, 22, 234-241.	0.9	26
588	The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond. Expert Review of Clinical Immunology, 2019, 15, 123-134.	1.3	54
589	The role of C-reactive protein as a predictor of treatment response in patients with ankylosing spondylitis. Seminars in Arthritis and Rheumatism, 2019, 48, 997-1004.	1.6	20
590	Structural progression rate decreases over time on serial radiography and magnetic resonance imaging of sacroiliac joints and spine in a five-year follow-up study of patients with ankylosing spondylitis treated with tumour necrosis factor inhibitor. Scandinavian Journal of Rheumatology, 2019, 48, 185-197.	0.6	20
591	Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study. RMD Open, 2019, 5, e000585.	1.8	41
593	Differences in Palmoplantar Pustulosis and Psoriasis Vulgaris in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis Treated with Biological Therapy. Journal of Rheumatology, 2019, 46, 117-118.	1.0	2
594	Recommendations for the Prescription of Physical Exercise for Patients With Spondyloarthritis. ReumatologĀa ClĀnica (English Edition), 2019, 15, 77-83.	0.2	2
595	Ankylosing spondylitis: A novel risk factor for atrial fibrillation – A nationwide population-based study. International Journal of Cardiology, 2019, 275, 77-82.	0.8	31
596	Validaci3n al idioma espaol de Venezuela de los Āndices de actividad de enfermedad y el Āndice funcional para espondilitis anquilosante. ReumatologĀa ClĀnica, 2019, 15, 223-228.	0.2	2
597	Recomendaciones para la prescripci3n de ejercicio fĀsico en pacientes con espondiloartritis. ReumatologĀa ClĀnica, 2019, 15, 77-83.	0.2	9
598	Janus kinase-1 and 3 in ankylosing spondylitis. Journal of the Formosan Medical Association, 2019, 118, 134-141.	0.8	12
600	Associated factors with adherence to standard exercise therapy and health-related quality of life in Chinese patients with ankylosing spondylitis. Modern Rheumatology, 2020, 30, 149-154.	0.9	10
601	Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J). Modern Rheumatology, 2020, 30, 132-140.	0.9	25
602	Disease Activity Cutoff Values in Initiating Tumor Necrosis Factor Inhibitor Therapy in Ankylosing Spondylitis: A German GO-NICE Study Subanalysis. Journal of Rheumatology, 2020, 47, 35-41.	1.0	6
603	Is the whole-body cryotherapy a beneficial supplement to exercise therapy for patients with ankylosing spondylitis?. Journal of Back and Musculoskeletal Rehabilitation, 2020, 33, 185-192.	0.4	14
604	The effectiveness of aquatic physical therapy intervention on disease activity and function of ankylosing spondylitis patients: a meta-analysis. Psychology, Health and Medicine, 2020, 25, 832-843.	1.3	7

#	ARTICLE	IF	CITATIONS
605	Measuring bone density in axial spondyloarthropathy: Time to turn things on their side?. International Journal of Rheumatic Diseases, 2020, 23, 358-366.	0.9	9
606	Do NSAIDs affect radiographic progression in axial SpA?. Nature Reviews Rheumatology, 2020, 16, 9-10.	3.5	2
607	Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate. BMJ Open, 2020, 10, e039059.	0.8	7
608	Patient-Reported Outcomes Following Inpatient Multimodal Treatment Approach in Chronic Pain-Related Rheumatic Diseases. Global Advances in Health and Medicine, 2020, 9, 216495612094881.	0.7	4
609	National pharmacological treatment trends for ankylosing spondylitis in South Korea: A national health insurance database study. PLoS ONE, 2020, 15, e0240155.	1.1	2
610	Effects of exercise programmes on pain, disease activity and function in ankylosing spondylitis: A meta-analysis of randomized controlled trials. European Journal of Clinical Investigation, 2020, 50, e13352.	1.7	10
611	<p>Preoperative Planning and the Use of Free Available Software for Sagittal Plane Corrective Osteotomies of the Lumbar Spine in Ankylosing Spondylitis</p>. Orthopedic Research and Reviews, 2020, Volume 12, 171-182.	0.7	3
612	Effects of types and degrees of ankylosing spondylitis hip structural damages on post-total hip arthroplasty outcome measurements. Medicine (United States), 2020, 99, e23174.	0.4	2
613	Chinese herbal medicine Yanghe decoction for ankylosing spondylitis. Medicine (United States), 2020, 99, e23466.	0.4	1
614	Atherosclerosis in Rheumatology: Old and New Insights. , 0, , .		0
615	Two pediatric cases of isotretinoin-induced sacroiliitis successfully treated with adalimumab. Pediatric Dermatology, 2020, 37, 929-931.	0.5	2
616	Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5. Chinese Medical Journal, 2020, 133, 2521-2531.	0.9	23
617	Patients' experiences with goal pursuit after discharge from rheumatology rehabilitation: A qualitative study. Musculoskeletal Care, 2020, 19, 249-258.	0.6	5
618	Does Belonging to a Patient Association Is of Help for Patients with Axial Spondyloarthritis? Results from the Atlas Survey. Current Rheumatology Reports, 2020, 22, 22.	2.1	4
619	Sleep apnea—hypopnea syndrome caused by ankylosing spondylitis. Medicine (United States), 2020, 99, e20055.	0.4	4
620	Juvenile idiopathic arthritis in Southeast Asia: the Singapore experience over two decades. Clinical Rheumatology, 2020, 39, 3455-3464.	1.0	12
621	Patients with Axial Spondyloarthritis Are at Risk of Developing Adhesive Capsulitis: Real-World Evidence Database Study in Taiwan. Journal of Clinical Medicine, 2020, 9, 787.	1.0	4
622	An update on serum biomarkers to assess axial spondyloarthritis and to guide treatment decision. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2093427.	1.2	20

#	ARTICLE	IF	CITATIONS
623	Comparative efficacy and safety of secukinumab and ixekizumab in patients with active ankylosing spondylitis. <i>Zeitschrift Fur Rheumatologie</i> , 2020, 80, 776-784.	0.5	0
624	Recommendations by the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the treatment of patients with inflammatory bowel disease associated with spondyloarthritis. <i>GastroenterologĀa Y HepatologĀa (English Edition)</i> , 2020, 43, 273-283.	0.0	3
626	<p>Treatment Pattern Analysis and Health-care Resource Consumption on Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Biological Drugs in a Northern Italian Region</p>. <i>Therapeutics and Clinical Risk Management</i> , 2020, Volume 16, 509-521.	0.9	1
627	Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial. <i>BioDrugs</i> , 2020, 34, 381-393.	2.2	21
628	The comparative efficacy of supervised- versus home-based exercise programs in patients with ankylosing spondylitis. <i>Medicine (United States)</i> , 2020, 99, e19229.	0.4	20
629	Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations. <i>Gut</i> , 2020, 69, 617-629.	6.1	71
631	Moxibustion for the treatment of ankylosing spondylitis: a systematic review and meta-analysis. <i>Annals of Palliative Medicine</i> , 2020, 9, 709-720.	0.5	10
632	Impact of persistence with tumour necrosis factor inhibitors on healthcare resource utilization and costs in chronic inflammatory joint diseases. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 163-177.	1.1	6
633	Multidimensional Health Assessment Questionnaire as an Effective Tool to Screen for Depression in Routine Rheumatology Care. <i>Arthritis Care and Research</i> , 2021, 73, 120-129.	1.5	9
634	Combination of methotrexate and sulfasalazine is an efficacious option for axial spondyloarthritis in a resource-limited, real-world clinical setting: a prospective cohort study. <i>Clinical Rheumatology</i> , 2021, 40, 1871-1879.	1.0	8
635	Outcomes and predictors of juvenile idiopathic arthritis in Southeast Asia: a Singapore longitudinal study over a decade. <i>Clinical Rheumatology</i> , 2021, 40, 2339-2349.	1.0	6
636	Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies. <i>Rheumatology and Therapy</i> , 2021, 8, 273-288.	1.1	11
637	Psychological factors associated with sleep disorders in patients with axial spondyloarthritis or psoriatic arthritis: A multicenter cross-sectional observational study. <i>Journal of Clinical Nursing</i> , 2021, 30, 266-275.	1.4	12
638	Incidence and case fatality rate of COVID-19 in patients with inflammatory articular diseases. <i>International Journal of Clinical Practice</i> , 2021, 75, e13707.	0.8	13
640	Recommendations of the Mexican College of Rheumatology for the management of spondyloarthritis. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2021, 17, 37-45.	0.2	0
641	Ankylosing Spondylitis in a 44-Year-Old Nigerian Man: A Case Report. <i>Journal of Biosciences and Medicines</i> , 2021, 09, 51-58.	0.1	0
642	MANAGEMENT OF A PATIENT WITH ANKYLOSING SPONDYLITIS TYPE SPONDYLOARTHRITIS AND LATENT TUBERCULOSIS INFECTION. <i>Current Internal Medicine Research and Practice Surabaya Journal</i> , 2021, 2, 19.	0.0	0
643	Rheumatologic Rehabilitation. , 2021, , 606-626.e1.		3

#	ARTICLE	IF	CITATIONS
644	Multi-target mechanism of <i>Tripterygium wilfordii</i> Hook for treatment of ankylosing spondylitis based on network pharmacology and molecular docking. <i>Annals of Medicine</i> , 2021, 53, 1091-1099.	1.5	36
645	Low-Back Pain. , 2021, , 127-138.		3
646	A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2021, 48, 1259-1267.	1.0	8
647	Effectiveness, safety and economic analysis of Benepali in clinical practice. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2021, 17, 588-594.	0.2	2
648	Impact of assessing patient-reported outcomes with mobile apps on patientĀ-provider interaction. <i>RMD Open</i> , 2021, 7, e001566.	1.8	14
649	The Prognostic Value of Pain Phenotyping in Relation to Treatment Outcomes in Patients with Axial Spondyloarthritis Treated in Clinical Practice: A Prospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 1469.	1.0	0
650	Development and Validation of 3 Preliminary MRI Sacroiliac Joint Composite Structural Damage Scores in a 5-year Longitudinal Axial Spondyloarthritis Study. <i>Journal of Rheumatology</i> , 2021, 48, 1537-1546.	1.0	6
651	The bone bridge significantly affects the decrease in bone mineral density measured with quantitative computed tomography in ankylosing spondylitis. <i>PLoS ONE</i> , 2021, 16, e0249578.	1.1	5
652	Efficacy of warming needle moxibustion in the treatment of ankylosing spondylitis. <i>Medicine (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf</i>	0.4	3
653	Long-term therapy with non-steroidal anti-inflammatory drugs for axial spondyloarthritis: focus on changes in liver function. <i>Eksperimental' naya I Klinicheskaya Gastroenterologiya</i> , 2021, , 152-157.	0.1	0
655	GO-BEYOND: a real-world study of persistence of golimumab in patients with axial spondyloarthritis and rheumatoid arthritis in Turkey. <i>Immunotherapy</i> , 2021, 13, 841-850.	1.0	6
656	Persistence to Biologic Therapy Among Patients With Ankylosing Spondylitis: An Observational Study Using the OPAL Dataset. <i>Journal of Rheumatology</i> , 2022, 49, 150-156.	1.0	5
657	Predictors of Health-Related Quality of Life in Patients with Ankylosing Spondylitis in Southwest China. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 1887-1894.	0.8	3
658	Masterclass: Axial spondyloarthritis for osteopaths and manual therapists. <i>International Journal of Osteopathic Medicine</i> , 2021, 41, 45-56.	0.4	2
659	Investigation of asymptomatic intestinal inflammation in ankylosing spondylitis by fecal calprotectin. <i>Arab Journal of Gastroenterology</i> , 2021, , .	0.4	2
660	Ankylosing Spondylitis and Risk of Cardiac Arrhythmia and Conduction Disorders: A Systematic Review and Meta-analysis. <i>Current Cardiology Reviews</i> , 2021, 17, e150521193326.	0.6	5
661	Treatment Persistence in Patients Cycling on Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors in Inflammatory Arthritis: A Retrospective Study. <i>Advances in Therapy</i> , 2021, , 1.	1.3	3
662	Efficacy and safety of warm acupuncture in the treatment of ankylosing spondylitis. <i>Medicine (United Tj ETQq1 1 0.784314 rgBT /Overl</i>	0.4	3

#	ARTICLE	IF	CITATIONS
664	A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis. <i>Modern Rheumatology</i> , 2012, 22, 589-597.	0.9	12
665	MR-defined fat infiltration of the lumbar paravertebral muscles differs between non-radiographic axial spondyloarthritis and established ankylosing spondylitis. <i>Modern Rheumatology</i> , 2013, 23, 811-816.	0.9	15
668	Comparative effectiveness and persistence of TNFi and non-TNFi in juvenile idiopathic arthritis: a large paediatric rheumatology centre in the USA. <i>Rheumatology</i> , 2021, 60, 4063-4073.	0.9	7
669	Clinical Efficacy of Modified Yanghe Decoction in Ankylosing Spondylitis: A Randomized Controlled Trial. <i>Medical Science Monitor</i> , 2018, 24, 2912-2918.	0.5	10
670	Physical Activity Assessment in Patients with Axial Spondyloarthritis Compared to Healthy Controls: A Technology-Based Approach. <i>PLoS ONE</i> , 2014, 9, e85309.	1.1	73
671	Efficacy of High Intensity Exercise on Disease Activity and Cardiovascular Risk in Active Axial Spondyloarthritis: A Randomized Controlled Pilot Study. <i>PLoS ONE</i> , 2014, 9, e108688.	1.1	83
672	Expression of Prostaglandin E2 Enzymes in the Synovium of Arthralgia Patients at Risk of Developing Rheumatoid Arthritis and in Early Arthritis Patients. <i>PLoS ONE</i> , 2015, 10, e0133669.	1.1	9
673	Impact of Dose Tapering of Tumor Necrosis Factor Inhibitor on Radiographic Progression in Ankylosing Spondylitis. <i>PLoS ONE</i> , 2016, 11, e0168958.	1.1	27
674	Genetics in TNF-TNFR pathway: A complex network causing spondyloarthritis and conditioning response to anti-TNFi therapy. <i>PLoS ONE</i> , 2018, 13, e0194693.	1.1	17
678	Variations in gut microbial profiles in ankylosing spondylitis: disease phenotype-related dysbiosis. <i>Annals of Translational Medicine</i> , 2019, 7, 571-571.	0.7	29
679	Comparison of Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis from a Single Rheumatology Hospital in Morocco. <i>Current Rheumatology Reviews</i> , 2020, 16, 240-244.	0.4	4
680	Drug Levels and Antibodies Against TNF-blockers in Spondyloarthritis and Rheumatoid Arthritis are Associated with the Activity but they do Not Predict it. <i>Current Rheumatology Reviews</i> , 2019, 15, 329-335.	0.4	5
681	Baseline Characteristics of Patients with Ankylosing Spondylitis and Psoriatic Arthritis Treated with Secukinumab in the Real-World Setting: AQUILA, a Non-Interventional Study. <i>Open Rheumatology Journal</i> , 2019, 13, 53-60.	0.1	1
682	Physical Activity Assessment Using an Activity Tracker in Patients with Rheumatoid Arthritis and Axial Spondyloarthritis: Prospective Observational Study. <i>JMIR MHealth and UHealth</i> , 2018, 6, e1.	1.8	48
683	A case of essential thrombocythemia and ankylosing spondylitis treated with a combination of anagrelide, disease-modifying antirheumatic drugs, and etanercept. <i>Srpski Arhiv Za Celokupno Lekarstvo</i> , 2016, 144, 81-84.	0.1	2
684	Tumour necrosis factor-Î± inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2016, 20, 1-334.	1.3	62
685	Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations. <i>World Journal of Gastroenterology</i> , 2015, 21, 10274.	1.4	78
686	Bushen-Qiangdu-Zhily decoction inhibits osteogenic differentiation of rat fibroblasts by regulating connexin 43. <i>Experimental and Therapeutic Medicine</i> , 2016, 12, 347-353.	0.8	3

#	ARTICLE	IF	CITATIONS
687	The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus. Korean Journal of Internal Medicine, 2020, 35, 41-59.	0.7	20
688	Biologic Agents in Rheumatic Diseases. Korean Journal of Medicine, 2012, 82, 549.	0.1	3
689	The Use of Biological Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in Korea: Results of a Korean Expert Consensus. Journal of Rheumatic Diseases, 2020, 27, 4.	0.4	17
690	Rheumatologic rehabilitation: the great expectation for millions of rheumatologic patients. Reumatismo, 2012, 64, 1-6.	0.4	4
691	Adalimumab as a successful treatment for acne fulminans and bilateral acute sacroiliitis with hip synovitis complicating isotretinoin therapy. Indian Journal of Dermatology, Venereology and Leprology, 2018, 84, 104.	0.2	18
692	Overview of Drug Therapy for Spondyloarthritis. Rheumatology (Sunnyvale, Calif), 2013, 03, .	0.3	3
693	Treatment Patterns and Costs for Anti-TNF± Therapy in Patients with Ankylosing Spondylitis. Rheumatology (Sunnyvale, Calif), 0, s6, .	0.3	3
694	A Simple Approach of Low Back Pain. International Journal of Clinical Medicine, 2014, 05, 1087-1098.	0.1	4
695	Health Benefits of Exercise. FTR - Turkiye Fiziksel Tip Ve Rehabilitasyon Dergisi, 2014, 60, 9-14.	0.1	12
696	Biological therapies in rheumatic diseases. Clinica Terapeutica, 2013, 164, e413-28.	0.2	37
697	Comment mettre en place un protocole de recherche clinique concernant lâ€™Ã©valuation dâ€™une thÃ©rapie complÃ©mentaire lorsquâ€™on ne vient ni du milieu mÃ©dical ni de celui de la recherche?. HEGEL - HEpato-GastroEntÃ©rologie LibÃ©rale, 2021, NÂ° 3, 276-284.	0.0	0
698	Paravertebral Muscle Mechanical Properties in Patients with Axial Spondyloarthritis or Low Back Pain: A Case-Control Study. Diagnostics, 2021, 11, 1898.	1.3	8
699	Hip Replacement in Ankylosing Spondylitis Patients with Advanced Hip Involvement: Factors Associated with Bilateral Total Hip Arthroplasty. International Journal of General Medicine, 2021, Volume 14, 6857-6862.	0.8	3
700	Spondyloarthritiden. , 2012, , 59-101.		0
701	Lâ€™apport et les indications des biothÃ©rapies dans les rhumatismes inflammatoires. Bulletin De L'Academie Nationale De Medecine, 2012, 196, 1279-1293.	0.0	0
703	Muskuloskelettale Infektionen. , 2013, , 214-229.		0
704	Weight Gain and Improvement of Osteoporosis with Anti-TNF Therapy. Korean Journal of Medicine, 2013, 85, 485.	0.1	0
705	Updates of Spondyloarthrothy Treatment. Korean Journal of Medicine, 2013, 85, 256.	0.1	1

#	ARTICLE	IF	CITATIONS
706	OPO096-HPRâ€¦Benefits of Progressive Muscle Strengthening Using a Swiss Ball in Patients with Ankylosing Spondylitis: A Randomized Controlled Trial. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A82.3-A83.	0.5	0
707	Lower Extremity Arthroplasty in Patients With Inflammatory Arthritis: Preoperative and Perioperative Management. <i>Journal of the American Academy of Orthopaedic Surgeons</i> , The, 2013, 21, 355-363.	1.1	14
714	THE INFLUENCE OF INFLIXIMAB THERAPY ON BONE MINERAL DENSITY IN PATIENTS WITH ANKYLOSING SPONDYLITIS. <i>Osteoporosis and Bone Diseases</i> , 2013, 16, 13-16.	0.3	0
715	Axiale Spondyloarthritis (einschlieÃŸlich ankylosierender Spondylitis). , 2014, , 1-16.		0
716	Management of Axial Spondyloarthritis. , 2014, , 59-96.		2
718	Infektreaktive bakterielle Arthritis. , 2015, , 1-6.		0
719	Management of ankylosing spondylitis/axial spondyloarthritis. , 2015, , 970-985.		1
721	Inflammatory Arthropathy of the Knee. , 2015, , 39-49.		0
723	State of play of CME in Europe in 2014: proceedings from the Seventh Annual Meeting of the European CME Forum. <i>Journal of European CME</i> , 2015, 4, 27680.	0.6	0
724	Niet-medicamenteuze therapie bij reumatische aandoeningen. , 2015, , 303-313.		0
725	EFFICACY AND SAFETY OF ADALIMUMAB IN ANKYLOSING SPONDYLITIS: DATA FROM REAL LIFE. <i>Romanian Journal of Rheumatology</i> , 2015, 24, 44-49.	0.0	1
726	ADVANCES IN THERAPIES FOR SPONDYLOARTHROPATHIES. , 2015, , 109-128.		0
727	A Flowchart For Understanding Ankylosing Spondylitis Management Recommendations of Asas/Eular. <i>Journal of Rheumatic Diseases and Treatment</i> , 2015, 1, .	0.1	0
728	Risk of Lymphoproliferative Disorders in Spondyloarthritis during Treatment with Methotrexate: A Case Report and Literature Review. <i>Rheumatology (Sunnyvale, Calif)</i> , 2016, 06, .	0.3	0
730	A gastroenterologist and a rheumatologist answer the questions on the use of non-steroidal anti-inflammatory drugs raised by primary care physicians. <i>Pediatria I Medycyna Rodzinna</i> , 2016, 12, 28-41.	2.3	0
731	Advantages of remote monitoring the activity of patients with axial spondylitis (progress study). <i>Klinicheskaia Meditsina</i> , 2016, 94, 279-285.	0.2	0
732	Prevalence of Human Leucocyte Antigen B17 in Spondyloarthritis Patients in a Tertiary Care Center in South India Detected Microlymphocytotoxicity Test. <i>International Journal of Current Microbiology and Applied Sciences</i> , 2016, 5, 592-598.	0.0	0
733	Rehabilitation bei rheumatischen Erkrankungen. , 2017, , 303-315.		0

#	ARTICLE	IF	CITATIONS
735	Implementing Shared Decision Making In Clinical Practice: Outcomes of a New Shared Decision Making Aid for Chronic Inflammatory Arthritis Patients. <i>Journal of Patient Care</i> , 2017, 02, .	0.1	2
736	A Needs-Based Rheumatologist Education Program on Treating to Target in Psoriatic Arthritis and Spondyloarthropathy: Insights and Challenges. <i>Open Journal of Rheumatology and Autoimmune Diseases</i> , 2017, 07, 53-64.	0.1	0
737	é•æœÿé—“æŠ—æŠ—TNF-î±è£½â%ã,æŠ•ăŽă—ăÿă¼ç’æ€šè,,šæŽç,Žă®2ă¾4«. <i>Orthopedics & Traumatology</i> , 2017, 06, 71-75.		
738	Spondyloarthritiden. , 2017, , 41-73.		0
740	ENDOTHELIAL DYSFUNCTION AND CARDIOVASCULAR RISK IN PATIENTS WITH ANKYLOSING SPONDYLITIS. <i>International Journal of Medicine and Medical Research</i> , 2017, , .	0.0	2
741	Effectiveness of Soft Tissue Mobilisation as an adjunct to the Conventional Therapy in patients with Ankylosing Spondylitis. <i>Journal of Novel Physiotherapy and Rehabilitation</i> , 0, , 001-014.	0.2	1
742	SAT0296â€…Patients with diffuse idiopathic skeletal hyperostosis and low back pain â€œ evaluation and rehabilitation. , 2018, , .		0
743	ACCORDING TO THE MATERIALS OF THE 2015/2016 NEW EUROPEAN LEAGUE AGAINST RHEUMATISM (EULAR) GUIDELINES FOR REDUCING CARDIOVASCULAR RISK IN PATIENTS WITH INFLAMMATORY ARTHRITIS: GENERAL CHARACTERIZATION AND DISCUSSION PROBLEMS. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2018, 56, 272-279.	0.2	3
744	VALIDATION OF THE EQ-5D-5L VERSION IN RUSSIA. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2018, 56, 351-355.	0.2	14
746	A New Medical Therapy for Axial Spondyloarthritis. <i>Korean Journal of Medicine</i> , 2018, 93, 424-429.	0.1	0
747	Gelenk- und Muskelschmerzen. <i>Springer Reference Medizin</i> , 2019, , 1-27.	0.0	0
748	Primary Biliary Cirrhosis and Ankylosing Spondylitis, A Rare Association. <i>Medicina Interna (Bucharest)</i> Tj ETQq1 1 0,784314 rgBT /Ove	0.1	0
749	Gelenk- und Muskelschmerzen. <i>Springer Reference Medizin</i> , 2019, , 347-373.	0.0	0
750	Extra-intestinal Manifestations. , 2019, , 165-172.		1
751	UTILIZATION PATTERNS OF DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS) IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES. <i>Farmacia</i> , 2019, 67, 184-192.	0.1	0
752	Adaptation of the Russian version of the ASAS health index. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2019, 57, 56-61.	0.2	1
753	Time course of changes in the clinical and instrumental manifestations of coxitis in patients with ankylosing spondylitis during golimumab therapy: a GO-COX study. Preliminary results. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2019, 57, 307-311.	0.2	5
754	A 33-Year-Old Patient with Persistent Back Pain. , 2020, , 241-247.		0

#	ARTICLE	IF	CITATIONS
755	Add-On Effects of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs in Ankylosing Spondylitis: Data from a Real-World Registered Study in China. <i>Medical Science Monitor</i> , 2020, 26, e921055.	0.5	3
756	The interchangeability of original tumor necrosis factor- α inhibitors and biosimilars in rheumatology: experience in replacing original infliximab with Flammagis for ankylosing spondylitis. <i>Sovremennaya Revmatologiya</i> , 2020, 14, 104-109.	0.1	0
757	The Trend of Targeted Therapies in Chinese Patients With Ankylosing Spondylitis: Results From a Real-Life Survey. <i>Frontiers in Pharmacology</i> , 2021, 12, 763707.	1.6	1
758	RHEUMATISCHE ERKRANKUNGEN. , 2020, , I-1-I8-7.		0
759	Inflammatory Diseases of the Hip Joint. , 2021, , 165-178.		0
760	Uveitis â€œ Possible adverse reaction to secukinumab in a patient with rehabilitation treatment for ankylosing spondylitis (case report). <i>Balneo Research Journal</i> , 2020, , 561-565.	0.4	1
761	MODERN VIEW ON THE PROBLEM OF OSTEOPOROSIS IN ANKYLOSING SPONDYLITIS. <i>Clinical Medicine and Pharmacology</i> , 2020, 5, 19-28.	0.1	0
762	Indirect comparison of NSAIDs for ankylosing spondylitis: Network meta-analysis of randomized, double-blind, controlled trials. <i>Experimental and Therapeutic Medicine</i> , 2020, 19, 3031-3041.	0.8	2
763	Disease activity in women with ankylosing spondylitis remains higher under Tumour Necrosis Factor inhibitor treatment than in men: a five-year observational study. <i>Scandinavian Journal of Rheumatology</i> , 2022, 51, 506-512.	0.6	6
764	Clinical Characteristics, Disease Activity, Functional Status, and Quality of Life Results of Patients With Psoriatic Arthritis Using Biological and Conventional Synthetic Disease-Modifying Antirheumatic Drugs. <i>Archives of Rheumatology</i> , 2021, 36, 1-9.	0.3	5
765	Efectividad, seguridad y anÃ¡lisis econÃ³mico de Benepali en prÃ¡ctica clÃ¡nica. <i>ReumatologÃ­a ClÃ¡nica</i> , 2021, 17, 588-594.	0.2	0
766	Immunogenicity of antitumor necrosis factor therapy in patients with spondyloarthritis. <i>Drug Metabolism and Personalized Therapy</i> , 2021, .	0.3	0
767	Diagnostic imaging characteristics of canine infectious sacroiliitis. <i>Canadian Veterinary Journal</i> , 2019, 60, 630-636.	0.0	3
768	Cardiac rehabilitation in a patient with ankylosing spondylitis: A single-program, double-effect. <i>Turkish Journal of Physical Medicine and Rehabilitation</i> , 2019, 65, 194-197.	0.3	1
769	Predicting functional disability in patients with spondyloarthritis using a CRP-based algorithm: A 3-year prospective study. <i>Experimental and Therapeutic Medicine</i> , 2021, 21, 89.	0.8	0
770	Infliximab therapy provides beneficial effects for choroidal thickness increase in patients with active ankylosing spondylitis: A possible mechanism mediating the suppressing of uveitis attacks. <i>Archives of Rheumatology</i> , 2021, 36, 56-62.	0.3	1
771	Disease modification in ankylosing spondylitis with TNF inhibitors: spotlight on early phase clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 1109-1124.	1.9	4
772	Objective Measurements of Physical Activity and Sedentary Behavior Using Wearable Devices in Patients With Axial Spondyloarthritis: Protocol for a Systematic Review. <i>JMIR Research Protocols</i> , 2021, 10, e23359.	0.5	1

#	ARTICLE	IF	CITATIONS
773	Efficacy and Safety of Wenbu Zhibi Granule in Patients with Ankylosing Spondylitis: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-9.	0.5	2
774	Health-Care and Societal Costs Associated with Non-Persistence with Subcutaneous TNF-Î± Inhibitors in the Treatment of Inflammatory Arthritis (IA): A Retrospective Observational Study. Advances in Therapy, 2021, , 1.	1.3	1
775	Ability to Participate in Social Activities of Rheumatoid Arthritis Patients Compared with Other Rheumatic Diseases: A Cross-Sectional Observational Study. Diagnostics, 2021, 11, 2258.	1.3	8
776	An Overview on the Role of Surgical Management in Ankylosing Spondylitis. Archives of Pharmacy Practice, 2021, 12, 106-111.	0.2	0
777	Analytical Method Development and Validation of Etanercept by UV and RP-UFLC Methods. American Journal of Analytical Chemistry, 2021, 12, 493-505.	0.3	2
779	Infliximab Therapy Provides Beneficial Effects for Choroidal Thickness Increase in Patients With Active Ankylosing Spondylitis: A Possible Mechanism Mediating the Suppressing of Uveitis Attacks. Archives of Rheumatology, 2021, 36, 56-62.	0.3	1
780	Predicting functional disability in patients with spondyloarthritis using a CRP-based algorithm: A 3-year prospective study. Experimental and Therapeutic Medicine, 2020, 21, 89.	0.8	1
781	Bone Involvement in Patients with Spondyloarthropathies. Calcified Tissue International, 2022, 110, 393-420.	1.5	7
782	Effectiveness of Physiotherapy in Patients with Ankylosing Spondylitis: A Systematic Review and Meta-Analysis. Healthcare (Switzerland), 2022, 10, 132.	1.0	12
783	Central sensitization has major impact on quality of life in patients with axial spondyloarthritis. Seminars in Arthritis and Rheumatism, 2022, 52, 151933.	1.6	16
784	Balneotherapy in spondyloarthropathy: A systematic review. Therapie, 2022, , .	0.6	2
785	Protective Effect and Possible Mechanisms of Tripterygium Glycosides in Patients with Ankylosing Spondylitis: A Systematic Review and Meta-Analysis. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-18.	1.9	3
786	Diagnosis of fibromuscular dysplasia after resection of splenic aneurysm. Annals of Vascular Surgery Brief Reports and Innovations, 2022, , 100072.	0.1	0
787	Rare Clinical Case of Cryopyrin-Associated Periodic Syndrome Presented with Ankylosing Spondylitis: A Case Report. Current Rheumatology Reviews, 2021, 17, .	0.4	0
788	Gender Differences in Ankylosing Spondylitis Patients with Advanced Hip Involvement: Results from A Matched Retrospective Cohort Study. Orthopaedic Surgery, 2022, 14, 405-410.	0.7	2
789	<sc>Fourth-Generation Ceramic-on-Ceramic THA</sc> in Patients with Ankylosing Spondylitis: A Minimum <sc>10-Year Follow-up</sc>. Orthopaedic Surgery, 2022, , .	0.7	3
790	The effectiveness of group and home-based exercise on psychological status in people with ankylosing spondylitis: A systematic review and meta-analysis. Musculoskeletal Care, 2022, 20, 758-771.	0.6	3
792	Alternative to Rituximab Therapy for a Patient with Ankylosing Spondylitis Who Was Unable to Continue Anti-TNF Therapy. Acta Medica Okayama, 2017, 71, 445-448.	0.1	0

#	ARTICLE	IF	CITATIONS
794	Deformity Surgery for Ankylosing Spondylitis. , 2017, , 1347-1352.e2.		0
795	Adalimumab Mitigates Lumbar Radiculopathy in a Case of Ankylosing Spondylitis. American Journal of Case Reports, 0, 23, .	0.3	0
796	Social economic costs of ankylosing spondylitis in Spain. Clinical and Experimental Rheumatology, 2021, 39, 357-364.	0.4	15
797	Discovery of CC-99677, a selective targeted covalent MAPKAPK2 (MK2) inhibitor for autoimmune disorders. Translational Research, 2022, 249, 49-73.	2.2	6
798	Immunogenicity of antitumor necrosis factor therapy in patients with spondyloarthritis. Drug Metabolism and Drug Interactions, 2021, 36, 25-32.	0.3	0
799	Investigating the Molecular Mechanism of Qianghuo Shengshi Decoction in the Treatment of Ankylosing Spondylitis Based on Network Pharmacology and Molecular Docking Analysis. Processes, 2022, 10, 1487.	1.3	1
800	Concomitant ankylosing spondylitis can increase the risk of biologics or small molecule therapies to control inflammatory bowel disease. Intestinal Research, 0, , .	1.0	1
801	A Real-World Study on the Effect of Imrecoxib for Patients with Axial Spondyloarthritis. Drug Design, Development and Therapy, 0, Volume 16, 2755-2765.	2.0	1
802	Microorganisms in the Pathogenesis and Management of Spondyloarthritis. , 2022, , 419-458.		0
803	Microorganisms in the Pathogenesis and Management of Ankylosing Spondylitis. , 2022, , 459-487.		0
806	Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis. Annals of the Rheumatic Diseases, 2023, 82, 130-141.	0.5	40
807	Do physical therapists follow evidence-based practices for treatment of inflammatory arthritis? Results from an online survey. Physiotherapy Theory and Practice, 2024, 40, 637-646.	0.6	1
808	Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. Annals of the Rheumatic Diseases, 2023, 82, 142-152.	0.5	23
809	Maintained activity in ankylosing spondylitis patients treated with TNFi and/or NSAID for at least 12 weeks: a cross-sectional study in Brazil. Advances in Rheumatology, 2022, 62, .	0.8	1
810	Effectiveness and safety of electroacupuncture for ankylosing spondylitis: A protocol for a systematic reviews and meta-analysis. Medicine (United States), 2022, 101, e31706.	0.4	0
811	Quality of life in patients with ankylosing spondylitis with anemic syndrome assessed according to the ASQoL questionnaire, the relationship with the course of the disease. BolĚ1, Sustavy, PozvonoĀnik, 2022, 12, 52-58.	0.1	0
812	Comparative Efficacy of Biologic Disease-Modifying Anti-Rheumatic Drugs for Non-Radiographic Axial Spondyloarthritis: A Systematic Literature Review and Bucher Indirect Comparisons. Rheumatology and Therapy, 2023, 10, 307-327.	1.1	1
813	Effectiveness and safety of ear acupuncture for ankylosing spondylitis: A protocol for systematic review and meta-analysis. Medicine (United States), 2022, 101, e32310.	0.4	0

#	ARTICLE	IF	CITATIONS
814	Arthritiden – Begutachtung. Springer Reference Medizin, 2023, , 1-7.	0.0	0
815	Axial Spondyloarthritis: An Evolving Concept. European Medical Journal Rheumatology, 0, , 98-102.	0.0	0
816	Spondyloarthritis: Pathogenesis, Clinical Manifestations, Diagnosis and Management. European Medical Journal (Chelmsford, England), 0, , 96-102.	3.0	1
817	Orientation of Osteotomized Vertebrae in Two-Level Pedicle Subtraction Osteotomy Play a Crucial Role in the Remodeling of Harmonious Sagittal Curve for Severe Thoracolumbar Kyphotic Deformity Caused by Ankylosing Spondylitis. Neurosurgery, 2023, Publish Ahead of Print, .	0.6	0
818	Knowledge mapping of biological disease-modifying anti-rheumatic drugs for axial spondyloarthritis: a bibliometric study. Clinical Rheumatology, 0, , .	1.0	0